



ALIBABA HEALTH
Information Technology Limited

阿里健康信息技术有限公司

(Incorporated in Bermuda with limited liability)

Stock code: 00241

The background features a blue-to-green gradient with a network of white nodes and lines. Various white icons are scattered throughout, including a microscope, speech bubbles, a heart with an ECG line, a cloud with an upload arrow, a lightbulb with gears, test tubes, a pill, a globe, a chemical structure, a clipboard with a checkmark, and a molecular structure. A faint binary code (0s and 1s) is visible in the background.

INTERIM REPORT 2017

CONTENTS

02	Corporate Information
03	Management Discussion and Analysis
16	Additional Information
	Unaudited Interim Financial Information
30	Independent Review Report
31	Interim Condensed Consolidated Statement of Profit or Loss
32	Interim Condensed Consolidated Statement of Comprehensive Income
33	Interim Condensed Consolidated Statement of Financial Position
35	Interim Condensed Consolidated Statement of Changes in Equity
37	Interim Condensed Consolidated Statement of Cash Flows
40	Notes to the Interim Condensed Consolidated Financial Statements



CORPORATE INFORMATION

BOARD OF DIRECTORS

Executive Director

Mr. WANG Lei (Chief Executive Officer)

Non-executive Directors

Mr. WU Yongming (Chairman)

Mr. TSAI Chung, Joseph

Ms. HUANG Aizhu

Mr. KANG Kai

Independent Non-executive Directors

Mr. YAN Xuan

Mr. LUO Tong

Mr. WONG King On, Samuel

Audit Committee

Mr. WONG King On, Samuel (Chairman)

Mr. YAN Xuan

Mr. LUO Tong

Remuneration Committee

Mr. YAN Xuan (Chairman)

Mr. WU Yongming

Mr. WONG King On, Samuel

Nomination Committee

Mr. WU Yongming (Chairman)

Mr. LUO Tong

Mr. WONG King On, Samuel

AUTHORIZED REPRESENTATIVES

Mr. WANG Lei

Ms. LEW Aishan, Nicole

COMPANY SECRETARY

Ms. LEW Aishan, Nicole

LEGAL ADVISORS

H.M. Chan & Co in association with Taylor Wessing

AUDITOR

Ernst & Young

Certified Public Accountants

REGISTERED OFFICE

Canon's Court

22 Victoria Street

Hamilton HM 12

Bermuda

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

26/F, Tower One

Times Square

1 Matheson Street

Causeway Bay

Hong Kong

PRINCIPAL PLACE OF BUSINESS IN PRC

Building B, Hong Tai Dong Jie

Greenland Center, Wangjing

Chaoyang District, Beijing

PRINCIPAL SHARE REGISTRAR (IN BERMUDA)

Estera Management (Bermuda) Limited

Canon's Court

22 Victoria Street

Hamilton HM 12

Bermuda

BRANCH SHARE REGISTRAR (IN HONG KONG)

Tricor Secretaries Limited

Level 22, Hopewell Centre

183 Queen's Road East

Hong Kong

PRINCIPAL BANKERS

China CITIC Bank International Limited

The Hongkong and Shanghai Banking

Corporation Limited

China Merchants Bank Co., Ltd.

COMPANY WEBSITE

www.irasia.com/listco/hk/alihealth/

MANAGEMENT DISCUSSION AND ANALYSIS

INDUSTRY OVERVIEW

China's economy has continued to operate within a reasonable range in 2017 trending towards stabilized and positive growth, with a year-on-year growth in gross domestic product (GDP) of 6.9% for the first half of the year. The further integration of the Internet, big data and artificial intelligence (AI) with the physical economy has provided a new impetus to drive economic development and promote optimization and upgrade of traditional industries in order to better satisfy the people's demands for a higher quality of life.

"Healthy China (健康中國)" is a key strategy for the next stage of China's development. The Chinese government has been improving its national health policies and encouraging the private sector to provide all-around health services to the population through all life stages. As the reform of the pharmaceutical and healthcare system in China continues, the national guidelines for the pharmaceutical and healthcare industries, the policy framework for the general medical and healthcare system and the direction of industry development have become clearer, and the favorable policies have created a conducive environment for the Chinese pharmaceutical sector to thrive. In 2017, the government promulgated a series of policies concerning drug distribution to speed up the implementation of the Two-invoice System* (兩票制) for drug procurement and sale, encourage the transformation and upgrade of drug circulation enterprises, promote "Internet+ drug circulation" and push ahead the reform and improvement of the supply security mechanism for drugs in short supply. Various ministries and commissions, including the National Health and Family Planning Commission (the "NHFPC"), also promulgated a number of healthcare policies addressing two key issues: intensifying the reform of public hospitals and encouraging private investment in the healthcare sector. The former issue is centred on separating drug dispensation from drug prescription, tiered diagnosis and treatment and the establishment of the medical treatment partnership system, while the latter pertains to developing third-party healthcare services, allowing licensed doctors to practice in multiple medical institutions and relaxing restrictions on the establishment of medical clinics. In the second half of 2017, with the aim of revitalizing healthcare investment, the NHFPC has intensified reform efforts by canceling or simplifying the pre-approval process and strengthening regulation during and after investment. Changes in the regulations governing market access will continue to invigorate the development of the healthcare industry.

China's pharmaceutical market has been flourishing in a healthy and stable manner, driven by growth in GDP, greater spending power, the aging population, urbanization and upgrade of consumption structure. According to the statistics published in the Annual Report on China's Pharmaceutical Distribution Industry, the size of China's pharmaceutical retail market was RMB367.9 billion in 2016, up 9.5% from that in 2015, and the year-on-year growth rate was 0.9 percentage point higher than that of the previous year. Such growth considerably outperformed the GDP growth rate of 6.7%. As the healthcare reform, which focuses on separating drug dispensation from drug prescription, continues to proceed, more and more hospital prescriptions are being fulfilled by third-parties, which offers enormous opportunities for the pharmaceutical retail sector. With the widening imbalance between the growing demand for medical and healthcare services and the limited supply of medical and healthcare resources, as well as the rising medical and healthcare spending of the population and the government, the application of digital technologies (e.g. digital healthcare products, big data, remote medical treatment and AI) in the medical field presents new ways to improve diagnosis and treatment efficiency, facilitate personal health management and help prevent and diagnose disease at an earlier stage, with the goal of saving pharmaceutical resources and costs. Despite the many challenges in terms of technological innovation, data security and business model reinvention, many players have also spotted, and are gearing themselves up to leverage upon, the huge market opportunities.

BUSINESS REVIEW

As the healthcare flagship of Alibaba Group Holding Limited (“**Alibaba Holding**”, together with its subsidiaries, “**Alibaba Group**”), Alibaba Health Information Technology Limited (the “**Company**”) (together with its subsidiaries, the “**Group**”), which mission is to “make good health achievable at the fingertips”, has been strengthening the foundation of its pharmaceutical and healthcare businesses and actively planning for its future. With its vision of “facilitating medicine through big data and using the Internet to change the face of healthcare to provide fair, affordable and accessible medical and healthcare services to 1 billion people”, the Group has been striving to expand its healthcare product sale and e-commerce platform services businesses, provide product tracking platforms and explore the development of intelligent medicine and personal health management services, while actively establishing a foothold in the fields of medical and healthcare big data and AI.

- **Healthcare product sales and services**

The Group has been actively utilizing Internet technologies to build a medical and healthcare product and service supply system that covers the whole industry chain and every supply channel. Capitalizing on its online platform strengths and its understanding of the market and users, the Group connects upstream industry chain players (e.g. manufacturers and leading distributors) to offline companies (e.g. pharmaceutical retail chains, Tmall Supermarket* (天貓超市), LST* (零售通) and Hema Supermarket* (盒馬鮮生)) to facilitate product circulation along the whole chain and to offer quality products to downstream players at competitive prices. A comprehensive supply system helps to boost efficiency in the supply chain by bringing manufacturers, distributors and consumers closer together so that manufacturers can deliver their professional services more directly to consumers. Such enhanced connection is conducive to satisfying consumer needs and exploring and creating new demand. During the current reporting period, the Group established good relationships with many pharmaceutical, nutritional health and healthcare supplement manufacturers, as well as leading pharmaceutical distributors in China, who are our important business partners.

At the same time, the Group also offers one-stop health solutions encompassing a wide range of products, content and convenient services revolving around hot consumer groups and scenarios which derive consumer demand. Such comprehensive solutions that integrate both online and offline functions allow manufacturers to deliver a comprehensive and high quality healthcare experience to consumers.

Healthcare product sales

The Group’s total revenue from healthcare product sales for the current reporting period amounted to RMB786.2 million. In particular, online sales from our self-operated AliHealth Pharmacy* (阿里健康大藥房) and AliHealth overseas flagship stores showed impressive growth, spurred on by the Group’s operational and brand strengths as well as its business team’s effective execution. There were also significant improvements in the performance and capability of our warehousing, logistics, customer service and other supporting systems and services, which facilitated better quality control over products and services as well as a deeper understanding of the specific demands of different consumer groups.

e-Commerce platform services

During the current reporting period, the Group continued to provide outsourced and value-added services, including merchant business development, customer support and technical support for certain pharmaceutical categories (including over-the-counter drugs, medical devices, contact lenses, family planning products, and medical and healthcare services) on the Tmall platform. The continued strong growth of the Tmall e-commerce platform for pharmaceutical-related categories resulted in stable and fast growth of service income of the Group. During the current reporting period, the Group also acquired the health food category e-commerce platform services business from Alibaba Group. As Chinese disposable income has increased, so has healthcare awareness, even though the penetration rate of, and per capita spending on, healthcare products in China remain far lower than those of countries such as the United States and Japan. As the Chinese healthcare product market continues to become more compliant, the market has a promising future with enormous potential. Total revenue from e-commerce platform services comprising these two operations amounted to RMB66.6 million for the current reporting period.

Future prospects

Despite the issues facing the Chinese pharmaceutical and healthcare market, there is enormous room for development. To mitigate the problems of high dispersion of distributors and an excessively long supply chain of pharmaceutical and healthcare products, the Group will continue to work on enhancing the transparency and efficiency of the pharmaceutical and healthcare product supply chain through the use of the Internet and developing a more efficient drug distribution network for the benefit of market participants and consumers.

With regard to the problems encountered by consumers when they procure medical and healthcare products and services, the Group will continue its efforts to build the best platform with the best services for merchants and consumers and through the use of technology and business model innovation that will enable comprehensive and personalized interfacing with users with better quality control and user experience.

- **Intelligent medicine and health management services**

The Group has been actively cooperating with governments, hospitals, research institutes, colleges and other third-party organizations to explore the Internet+ healthcare intelligent medicine model, which covers areas such as medical research platforms, immersion training bases for practitioners, clinical decision support systems, cloud-based remote imaging platforms, Internet medical associations and solutions for blockchain data security. By integrating online and offline medical data and capitalizing on its strong cloud computing and healthcare big data mining and analytical capability, the Group has established an AI medical system to explore the application of AI engines. During the current reporting period, the Group launched its AI medical system “Doctor You”, and made considerable progress in the development of intelligence engines in areas such as image examination and chronic disease screening.

The Group signed agreements with each of The First Affiliated Hospital of Medical School of Zhejiang University, The Second Affiliated Hospital of Zhejiang University School of Medicine and Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine to promote the application of intelligent medicine in three fields, namely AI research, talent development and smart hospitals. Initiatives under these



MANAGEMENT DISCUSSION AND ANALYSIS

agreements include: establishing a laboratory for medical AI projects to promote the application of technologies such as AI and data mining in medical rescue and treatment in Zhejiang; setting up a national medical talent intelligent training platform that connects medical institutions and private establishments and enterprises across the country to develop an intelligent training management platform for practitioners that provides standardized, information and program-based systematic training; and establishing a model smart hospital, which includes building a mixed hospital cloud platform, a pediatric medical association cloud platform and a medical research data platform, and enabling mobile payments for all hospital services in the hospital.

During the current reporting period, the Group actively organized the provision of comprehensive, multi-tiered, professional and convenient health consultation and other services by third-party professionals such as medical practitioners and pharmacists via end-user applications such as the AliHealth mobile application and the Taobao, Tmall and Alipay mobile applications. The Group also strived to develop its personal health management platform, which integrates online and offline medical and health data to generate personal health profiles so as to facilitate the provision of personalized medical services and total health cycle management services. During the current reporting period, the Group further collaborated with renowned pharmaceutical enterprises to promote and provide online popular science education and offer online reservation services in relation to category 2 vaccines, thereby enabling the public to access diversified disease prevention services more conveniently.

Future prospects

The Internet, big data and various innovative technologies have created new opportunities to solve the issues facing the medical and healthcare sector. In 2016 and 2017, the State Council issued notices regarding the Guiding Opinions of the General Office of the State Council on Promoting and Regulating the Development of Healthcare Big Data Applications* (《國務院辦公廳關於促進和規範健康醫療大數據應用發展的指導意見》) and the Development Plan for the New Generation of Artificial Intelligence* (《新一代人工智能發展規劃》) respectively, stating the need to keep up with the latest developments in information technology and its goals to regulate and promote the integration, sharing and open application of healthcare and medical big data; and identifying AI as a strategic technology for the future, thereby signifying that the Internet+ Healthcare campaign is entering the era of cutting-edge technologies such as big data, AI technologies and cloud medical associations. Against this backdrop, the Group aspires to create a closed loop of comprehensive intelligent medical services by linking governments, medical institutions, patients and healthcare professionals through such major products as Internet hospital, AI healthcare solutions and health management tools with its big data and AI healthcare technologies and services.

In cooperation with its partners, the Group will continue to provide healthcare big data applications and solutions to governments and offer information-based and intelligent solutions for medical institutions of different levels to become a platform through which hospital information system technology companies can provide their services. The AliHealth platform will empower different participants in the healthcare industry chain by allowing convenient access and high quality services, to provide consumers with easy access to intelligent medical services. Furthermore, the Group, alongside those who share the same vision, will seek to create personalized electronic health profiles for the public through the application of big data analysis. We

aim to promote integrated healthcare services covering prevention, treatment, rehabilitation and health management throughout the life cycle, and to provide healthcare professionals with big data and AI-based diagnosis and treatment support tools, thereby improving service efficiency and capability.

- **Tracking services**

The Chinese government has continued to roll out important policies to strengthen product tracking in recent years. In early 2017, seven ministries and administrations including the Ministry of Commerce jointly issued the Guiding Opinion on Promoting the Construction of Key Product Information Tracking Systems* (《關於推進重要產品信息化追溯體系建設的指導意見》), which stated that promoting the construction of key product information tracking systems is an important measure for improving people's livelihoods, stimulating consumption, ensuring stable growth and furthering supply side structural reform, and is very important in terms of improving supply chain efficiencies and product quality and safety standards, encouraging circulation transformation, upgrade and innovation, establishing information-based monitoring and regulatory systems, as well as fostering a safe environment for consumption.

As disclosed in the Company's annual report 2017 published on June 25, 2017, following the publication by the China Food and Drug Administration (the "CFDA") of the Decision of the China Food and Drug Administration Regarding Amendment of the Good Supply Practice for Pharmaceutical Products (CFDA Order No. 28)* (《國家食品藥品監督管理總局關於修改〈藥品經營質量管理規範〉的決定》(國家食品藥品監督管理總局令第28號)) (the "Order No. 28"), the Company continued to work on the operation and finalization of the product identification, authentication and tracking system for the drug industry (the "Drug PIATS") under CFDA's direction while continuing to promote its Ma Shang Fang Xin* (碼上放心) tracking platform, which was launched in May 2016.

The Ma Shang Fang Xin tracking platform offers product tracking and related value-added services to help manufacturers establish product tracking systems to realize quality assurance and marketing control. By leveraging on the strong computational and data processing capacity of Alibaba Cloud, this platform is capable of processing mega-sized big data and supporting several hundred thousand corporate users at the same time with its sound compatibility, accessibility and security. This platform also helps quality manufacturers to have more interaction with, and hence better serve, its end consumers using tracking codes.

During the current reporting period, the Ma Shang Fang Xin tracking platform grew steadily in terms of customer development and industry coverage. As at the end of the current reporting period, more than 7,200 enterprises from the drug, food, alcohol, nutritional product and healthcare supplement, cosmetics, agricultural produce, fast-moving consumer goods and other industries had signed up with the Group to join the platform. For the pharmaceutical sector, the number of pharmaceutical manufacturers which signed up accounted for more than 80% of the total number of pharmaceutical manufacturers in China.

The Group also launched cross-border product tracking services during the current reporting period. Merchants directly procure the products from their country of origin and can collect inventory and test report information provided by institutions at that country of origin. Tracking records at key points during the product importation and circulation process are also available to ensure authenticity of the product and its country of origin.

MANAGEMENT DISCUSSION AND ANALYSIS

Future prospects

Ensuring drug and food safety for the benefit of the people is an important Chinese government policy, and the electronic tracking system is an important means for the government to strengthen product safety management for key items such as drugs and food. The Group will continue its efforts to construct tracking systems based on its platform operation experience and to maintain the accessibility and compatibility of its platforms. It will also work with different enterprises, industry organizations and the government to build information-based and intelligent management infrastructure and establish highly interactive platforms to connect manufacturers, testing and certification organizations, regulatory authorities and consumers, with the ultimate goal of developing a safe and reliable information channel between businesses and consumers.

FINANCIAL REVIEW

The key financial figures of the Group for the six months ended September 30, 2017 and the comparative figures for the six months ended September 30, 2016 are summarized as follows:

	For the six months ended September 30,		
	2017 RMB'000	2016 RMB'000	Change %
Revenue	889,731	55,027	1,516.9
Gross profit	255,488	47,529	437.5
Gross profit margin	28.7%	86.4%	N/A
Fulfillment	(146,850)	(821)	17,786.7
Sales and marketing expenses	(86,471)	(49,566)	74.5
Administrative expenses	(57,313)	(51,543)	11.2
Product development expenses	(61,377)	(50,441)	21.7
Other income and gains	17,244	6,143	180.7
Interest on bank loans	(5,134)	(2,055)	149.8
Other expenses	(2,199)	(11,075)	(80.1)
Operating loss	(86,612)	(111,829)	(22.5)
Share of profits of a joint venture	3,017	4,478	(32.6)
Share of profits or losses of associates	(7,976)	2,574	(409.9)
LOSS FOR THE REPORTING PERIOD	(92,178)	(105,825)	(12.9)
Net loss attributable to owners of the parent	(90,911)	(102,398)	(11.2)
NON-GAAP ADJUSTMENTS			
Adjusted net loss	(34,442)	(49,337)	(30.2)

— Revenue

Revenue of the Group for the six months ended September 30, 2017 amounted to RMB889,731,000, representing an increase of RMB834,704,000 or 1,516.9% as compared to RMB55,027,000 for the six months ended September 30, 2016. The increase in revenue was attributable to the rapid growth in revenue

from healthcare product sales and e-commerce platform services during the current reporting period. During the corresponding period of the preceding year, these businesses had only just commenced operations and recorded less than one month of revenue.

— ***Healthcare product sales***

The Group's healthcare product sale business comprises the self-operated B2C pharmacy business and the B2B centralized procurement and distribution business. During the current reporting period, the self-operated B2C pharmacy business, which is operated through Alihealth Pharmacy and Alihealth overseas flagship stores, grew rapidly. Meanwhile, the Group entered the centralized healthcare product supply chain procurement and distribution business to offer quality and keenly priced products to downstream merchants by connecting them to the upstream supply chain and analyzing circulation data. During the current reporting period, revenue from the above healthcare product sale business amounted to RMB786,179,000.

— ***e-Commerce platform services***

Pursuant to the service agreement between the Group, and Zhejiang Tmall Network Co., Ltd.* (浙江天猫网络有限公司) and Zhejiang Tmall Technology Co., Ltd.* (浙江天猫技术有限公司) under Alibaba Group, the Group provides merchant business development, customer support, technical support and other outsourced and value-added services for certain pharmaceutical-related categories on the Tmall platform in consideration of certain service fees. In tandem with the steady growth of Tmall's pharmaceutical category e-commerce platform business, the service fee income therefrom has become a significant source of revenue and profit for the Group during the current reporting period. In June 2017, the Group acquired the health food category e-commerce platform services business from Alibaba Group. Following such acquisition, the Group provides e-commerce platform services to health food merchants on the Tmall platform in consideration of software service fees from them. During the current reporting period, aggregate revenue from both services amounted to RMB66,610,000.

— ***Tracking services***

During the current reporting period, the Ma Shang Fang Xin tracking platform grew steadily in terms of customer development and industry coverage and revenue from the tracking business, which largely comprised revenue from the provision of value-added services on the Ma Shang Fang Xin tracking platform, amounted to RMB9,437,000. By comparison, revenue from the tracking business which largely comprised revenue from the operation of the Drug PIATS in China for the corresponding period of the preceding year, amounted to RMB48,983,000. The business model of the Ma Shang Fang Xin tracking platform is different from that of operating the Drug PIATS in China as the Ma Shang Fang Xin tracking platform is focused on providing a wider range of value-added services to allow the Group to offer more comprehensive and innovative solutions to enterprises in both the drug and non-drug industries, in a way that will create greater synergies with other businesses of the Group and be accretive to the business as a whole.

— ***Innovative healthcare related services***

Apart from the above businesses, the Group also explored various forms of innovative value-added services in the healthcare sector, including the provision of comprehensive marketing services covering multiple channels throughout the whole chain to pharmaceutical brands, and collaborating with renowned pharmaceutical enterprises to provide popular science education and establishing online reservation platforms in relation to category 2 vaccines. During the current reporting period, revenue from these services and projects amounted to RMB27,505,000.

— **Gross profit and gross profit margin**

The Group recorded gross profit for the six months ended September 30, 2017 of RMB255,488,000, representing an increase of 437.5% as compared to RMB47,529,000 for the six months ended September 30, 2016. Gross profit margin for the current reporting period was 28.7% as compared to 86.4% for the corresponding period of the preceding year. During the corresponding period of the preceding year, gross profit was mainly derived from the tracking business of operating the Drug PIATS in China. However, the Group's business has undergone significant change during the current reporting period. The rapid growth of the healthcare product sales business, which generated relatively larger revenue but with a lower gross profit margin, resulted in a significant decrease in the overall gross profit margin.

— **Fulfillment**

Warehousing, logistics and customer service expenses incurred by the Group's self-operated healthcare product sales business were included in fulfillment costs. Fulfillment costs for the six months ended September 30, 2017 amounted to RMB146,850,000, representing a substantial increase from RMB821,000 for the corresponding period of the preceding year mainly due to the huge growth in turnover of the self-operated B2C pharmacy business.

— **Sales and marketing expenses**

Sales and marketing expenses for the six months ended September 30, 2017 amounted to RMB86,471,000, representing an increase of RMB36,905,000 or 74.5% as compared to RMB49,566,000 for the corresponding period of the preceding year. Such increase was mainly due to the rise in promotional costs to publicize self-operated stores as well as the increase in the headcount of the Group's sales function to cater for new businesses.

— **Administrative expenses**

Administrative expenses for the six months ended September 30, 2017 amounted to RMB57,313,000, representing an increase of RMB5,770,000 or 11.2% as compared to RMB51,543,000 for the corresponding period of the preceding year. Such increase was mainly due to the increase in management share-based compensation costs.

— **Product development expenses**

Product development expenses for the six months ended September 30, 2017 amounted to RMB61,377,000, representing an increase of RMB10,936,000 or 21.7% as compared to RMB50,441,000 for the corresponding period of the preceding year. Such increase was mainly due to the increased headcount of the Company's research and development function. During the current reporting period, the Group continued to recruit more information technology engineers in order to expand its healthcare service network, as well as to develop its health management platform and intelligent medical analysis engines.

— **Other income and gains**

Other income for the six months ended September 30, 2017 amounted to RMB17,244,000, representing an increase of RMB11,101,000 or 180.7% as compared to RMB6,143,000 for the corresponding period of the preceding year. Such increase was mainly attributable to an increase in foreign exchange gains for the current reporting period.

— **Interest on bank loans**

Interest on bank loans for the six months ended September 30, 2017 amounted to RMB5,134,000, representing an increase of RMB3,079,000 or 149.8% as compared to RMB2,055,000 for the corresponding period of the preceding year. Such increase was mainly due to the increase in the principal amount of loans during the second half of the preceding year.

— **Other expenses**

Other expenses for the six months ended September 30, 2017 amounted to RMB2,199,000, representing a decrease of RMB8,876,000 or 80.1% as compared to RMB11,075,000 for the corresponding period of the preceding year. Such decrease was mainly due to the absence of exchange loss in the six months ended September 30, 2017 as compared to the exchange loss of RMB9,735,000 for the corresponding period of the preceding year.

— **Share of profits of a joint venture**

Share of profits of a joint venture represented the share of net operating results of the Group's 49%-owned joint venture, Beijing Honglian 95 Information Industries Company Limited* (北京鴻聯九五信息產業有限公司) ("HL95"), which engages in telecommunications and information value-added services. The share of profits of HL95 for the six months ended September 30, 2017 amounted to RMB3,017,000, representing a decrease of RMB1,461,000 or 32.6% as compared to RMB4,478,000 for the corresponding period of the preceding year. Such decrease in the share of profits was mainly due to the slight decrease in the profits of the joint venture's call center business caused by intense market competition.

MANAGEMENT DISCUSSION AND ANALYSIS

– Share of profits or losses of associates

The Group actively invests in the healthcare sector. For the six months ended September 30, 2017, the Group's share of losses of associates amounted to RMB7,976,000 as the newly acquired associates are either still under business transformation or at the initial stage of their business development.

– Non-generally accepted accounting principles (“non-GAAP”) indicator in relation to loss for the period: Adjusted net loss

For the six months ended September 30, 2017, the Group's loss amounted to RMB92,178,000, representing a decrease of RMB13,647,000 or 12.9% as compared to RMB105,825,000 for the corresponding period of the preceding year. For the six months ended September 30, 2017, the Group's adjusted net loss amounted to RMB34,442,000, representing a decrease of 30.2% as compared to RMB49,337,000 for the corresponding period of the preceding year. The reduction in adjusted net loss was mainly attributable to the increase in gross profit in line with revenue growth of all businesses.

To supplement the Group's consolidated financial statements presented in accordance with Hong Kong Financial Reporting Standards (“**HKFRS**”), the Group has also reported its adjusted net loss, which is not required under, or presented in accordance with, HKFRS, as an additional financial indicator. We believe that such non-GAAP indicator is conducive to the comparison of operating performance across different periods and between different companies by eliminating the potential impact of items which are, in the view of our management, not indicative of our operating performance. We believe that such indicator provides investors and other parties with useful information which would enable them to understand and evaluate our consolidated operating results in the same manner as our management does. However, the adjusted net loss presented by us may not be comparable to similar indicators presented by other companies. Such non-GAAP indicator is subject to limitations as an analytical tool and should not be regarded as being independent from or a substitute for the analysis of our operating results or financial positions reported in accordance with HKFRS.

The adjusted net losses for the six months ended September 30, 2017 and 2016 set out in the table below represent adjustments to the most direct and comparable financial indicator calculated and presented in accordance with HKFRS (i.e., loss for the period):

	Six months ended September 30,	
	2017	2016
	RMB'000	<i>RMB'000</i>
Loss for the reporting period	92,178	105,825
Excluding		
– Share-based compensation expenses	57,736	56,488
Adjusted net loss	34,442	49,337

FINANCIAL RESOURCES, LIQUIDITY AND FOREIGN EXCHANGE EXPOSURES

The financial position of the Group as at September 30, 2017 and the corresponding comparative figures as at March 31, 2017 are summarized as follows:

	September 30, 2017	March 31, 2017
	<i>RMB'000</i>	<i>RMB'000</i>
Current assets	890,363	810,915
Including		
– Cash and cash equivalents (including fixed deposits with maturity within three months, and mainly denominated in Hong Kong dollars, United States dollars and Renminbi)	109,350	569,860
– Restricted cash	2,268	914
– Pledged deposits	265,115	–
– Trade receivables and other receivables	91,271	58,118
Current liabilities	798,743	353,472
Current ratio (current assets/current liabilities)	1.11	2.29
Quick ratio (cash and cash equivalents and trade receivables/current liabilities)	0.25	1.78
Shareholders' equity	1,122,579	1,177,836
Gearing ratio (bank loans/shareholders' equity)	N/A	N/A

Cash and cash equivalents including fixed deposits with maturity within three months decreased by RMB460,510,000 or 80.8% from RMB569,860,000 as at March 31, 2017 to RMB109,350,000 as at September 30, 2017. Such decrease mainly reflected investments in associates and the drawdown to finance the operating cash outflow of the Group for the six months ended September 30, 2017.

Trade receivables and other receivables increased by RMB33,153,000 or 57.0% from RMB58,118,000 as at March 31, 2017 to RMB91,271,000 as at September 30, 2017. Such increase mainly reflected the increase in amounts receivable from customers of the centralized procurement and distribution business during the six months ended September 30, 2017.

As at September 30, 2017, the Group had pledged certain assets with a net book value of approximately RMB265,115,000 for bank loans and banking facilities.

The decrease in current and quick ratios as at September 30, 2017 mainly reflected the decrease in cash and cash equivalents described above. The current ratio was 1.11 (March 31, 2017: 2.29) and the quick ratio was 0.25 (March 31, 2017: 1.78).



MANAGEMENT DISCUSSION AND ANALYSIS

Shareholders' equity decreased by RMB55,257,000 or 4.7% from RMB1,177,836,000 as at March 31, 2017 to RMB1,122,579,000 as at September 30, 2017, mainly reflecting the net loss of the Company for the current reporting period.

The balance of the Group's outstanding bank loans at fixed interest rates as at September 30, 2017 amounted to RMB200,000,000. For the maturity profile of the Group's bank borrowings, please refer to Note 17 to the condensed consolidated financial statements. As at September 30, 2017, the sum of the Group's cash and cash equivalents, restricted cash and pledged deposits exceeded that of the Group's bank loans and hence no net gearing ratio was shown (March 31, 2017: Nil). As at September 30, 2017, the Group had no material contingent liabilities.

The Group's operations and transactions are principally conducted in the PRC. The Group prudently managed its treasury functions and maintained a healthy liquidity position throughout the six months ended September 30, 2017. The board of directors (the "**Board**") closely monitors the Group's liquidity position to ensure that the liquidity structure of our assets, liabilities and other commitments can meet the Group's funding requirements from time to time. Other than a certain amount of bank balances and cash, most of the Group's bank balances and cash are placed in fixed deposits and are denominated in Hong Kong dollars, Renminbi and United States dollars, while other assets and liabilities are mainly denominated in either Hong Kong dollars or Renminbi. The Group changed its presentation currency from Hong Kong dollars to Renminbi starting from the year ended March 31, 2016 to better reflect its operations in the PRC and to be consistent with the internal reporting reviewed by the Directors. The Group does not have a foreign exchange hedging policy but the management will continue to closely monitor exchange rate fluctuations and will take appropriate measures to keep foreign exchange risk exposure to a minimum. The Group does not use any financial instruments for hedging purposes.

EMPLOYEES AND REMUNERATION POLICIES

The number of full-time employees of the Group as at September 30, 2017 was 403 (390 as at March 31, 2017). Total staff costs of the Group for the six months ended September 30, 2017 amounted to RMB153.8 million (RMB115.6 million for the six months ended September 30, 2016). All staff employed by the Group in Hong Kong participated in the Mandatory Provident Fund Scheme.

The Group's policy is to maintain a competitive pay structure and employees are rewarded based on their performance.

The Group has also adopted a share award scheme as approved by the shareholders of the Company on November 24, 2014 (the "**Share Award Scheme**"). Pursuant to the Share Award Scheme, the Board may grant awards in the form of restricted share units ("**RSUs**") or options to eligible participants, including the directors of the Company, the directors of the Company's subsidiaries, the employees of the Group or any other persons who, as determined by the Board in its absolute discretion, have contributed or will contribute to the Group. Details of the options and RSUs granted, lapsed and outstanding under the Share Award Scheme during the current reporting period are set out in note 20 to the condensed consolidated financial statements.

SIGNIFICANT INVESTMENTS, MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

On May 19, 2017, Hongyun Jiukang Data Technology (Beijing) Company Limited* (弘云久康數據技術(北京)有限公司) (“**Hongyun Jiukang**”), a subsidiary of the Company, entered into a capital increase agreement (the “**Target Holdco Capital Increase Agreement**”) with Jiahe Meikang (Beijing) Technology Co., Ltd* (嘉和美康(北京)科技股份有限公司) (“**Target Holdco**”), pursuant to which Hongyun Jiukang agreed to inject RMB291,176,470.59 in cash into the Target Holdco, of which RMB15,045,882 should be contributed to the increase in its registered capital, and RMB276,130,588.59 should be contributed to its capital reserve. Upon completion of the Target Holdco Capital Increase Agreement, the registered capital of the Target Holdco should be increased to RMB100,305,882, and the Target Holdco should be held as to 85% by the existing shareholders of the Target Holdco and 15% by Hongyun Jiukang.

On the same day, Hongyun Jiukang also entered into another capital increase agreement (the “**Target Subsidiary Capital Increase Agreement**”) with Beijing Jiamei Online Technology Co., Ltd* (北京嘉美在線科技有限公司) (“**Target Subsidiary**”), pursuant to which Hongyun Jiukang agreed to inject RMB40,000,000 in cash to the Target Subsidiary, of which RMB36,654,545 should be contributed to the increase in its registered capital, and RMB3,345,455 should be contributed to its capital reserve. Upon completion of the Target Subsidiary Capital Increase Agreement, the registered capital of the Target Subsidiary should be increased to RMB81,454,545, and the Target Subsidiary should be held as to 55% by the existing shareholder of the Target Subsidiary, Beijing Jiahe Meikang Information Technology Co., Ltd* (北京嘉和美康信息技術有限公司) and 45% by Hongyun Jiukang. For further information, please refer to the announcement of the Company dated May 19, 2017.

On May 18, 2017, the Company entered into a share purchase agreement with Ali JK Nutritional Products Holding Limited (the “**Vendor**”), a direct wholly-owned Subsidiary of Alibaba Holding, pursuant to which the Company agreed to acquire a 100% equity interest in Ali JK Nutritional Products Limited, an offshore holding vehicle incorporated under the laws of the British Virgin Islands by the Vendor to hold the target business which comprises all merchant relationships with the target merchants for the promotion and distribution of the Blue Cap Health Food products sold on Tmall.com and certain relevant marketing and operations personnel managing the relationships with the target merchants. The aggregate consideration was HK\$3,800,000,000 and was satisfied by the Company issuing 1,187,500,000 consideration shares to the Vendor at completion. For further information, please refer to the announcement of the Company dated May 19, 2017.

Save for the above, as at the date of this report, the Group does not have any concrete plans for material investments or acquisition of capital assets in the coming year. The Company will make further announcement in accordance with The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, where applicable, if any material investments and acquisition opportunities materialize.



ADDITIONAL INFORMATION

DIRECTORS

The Directors during the period and up to the date of this report were:

Executive Director:

Mr. Wang Lei (Chief Executive Officer)

Non-Executive Directors:

Mr. Wu Yongming (Chairman)

Mr. Tsai Chung, Joseph

Ms. Huang Aizhu

Mr. Kang Kai

Independent Non-Executive Directors:

Mr. Yan Xuan

Mr. Luo Tong

Mr. Wong King On, Samuel

CHANGE IN INFORMATION IN RESPECT OF DIRECTORS

The change in information of the Directors pursuant to Rule 13.51B(1) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) since the date of the Company’s 2017 annual report dated May 16, 2017 up to the date of this report is as below:

On November 24, 2017, Mr. Tsai Chung, Joseph, a non-executive Director, ceased to be a director of Momo Inc., the shares of which are listed on NASDAQ (stock code: MOMO).

SHARE AWARD SCHEME

At the special general meeting of the Company held on November 24, 2014 (the “**Adoption Date**”), the shareholders of the Company approved the adoption of a new share award scheme (the “**Share Award Scheme**”). Unless terminated earlier by the Board, the Share Award Scheme shall be valid and effective for a term of 10 years commencing on the Adoption Date. The Share Award Scheme shall remain in effect until November 23, 2024. The validity period of the options granted under the Share Award Scheme shall be ten years from the date of grant and the options shall lapse upon the expiry of the validity period.

Pursuant to the terms of the Share Award Scheme, the Board may, from time to time, at its absolute discretion and subject to such terms and conditions as it may think fit (including the basis of eligibility of each employee determined by the Board from time to time) select an employee or any other person for participation in the Share Award Scheme and determine the number of shares to be awarded (the **“Share Awards”**). The total number of shares in respect of which awards may be granted under the Share Award Scheme and any other share award schemes of the Company shall not exceed 3% of the shares in issue as at the Adoption Date (the **“Scheme Mandate Limit”**), or 3% of the shares in issue as at the new approval date of the renewed Scheme Mandate Limit.

The specific mandate granted by shareholders at the annual general meeting of the Company held on August 18, 2016 (the **“2016 Specific Mandate”**) authorized the Board to exercise all the powers of the Company to grant Share Awards. Such specific mandate was lapsed at the conclusion of the annual general meeting of the Company held on July 26, 2017, where the specific mandate was then renewed by the approval of the shareholders of the Company (the **“2017 Specific Mandate”**). During the current reporting period, the total number of shares underlying the Share Awards granted and which remained outstanding as at September 30, 2017 amounted to 135,794,450, 48,933,000 of which were granted pursuant to the 2016 Specific Mandate, and 22,893,200 of which were granted pursuant to the 2017 Specific Mandate. As at September 30, 2017, Share Awards in respect of a total of 258,513,907 underlying shares, which represent 2.76% of the Company’s total issued shares as at September 30, 2017, remain available to be granted under the Share Award Scheme under the 2017 Specific Mandate.

Details of the options and restricted share units (**“RSUs”**) granted and outstanding under the Share Award Scheme are as below:

Name of option holders/grantees of RSU	Nature	Number of shares represented by options or RSUs outstanding at March 31, 2017	Date of grant/conditional grant	Granted during the period	Exercise price (HK\$)	Options exercised during the period	Options or RSUs lapsed/cancelled during the period	RSUs vested during the period	Number of shares represented by options or RSUs outstanding at September 30, 2017
Director of the Company									
Mr. Wang Lei	Options	7,491,000	September 7, 2015 ⁽¹⁾	—	5.184	—	—	—	7,491,000
	RSUs	1,284,000	September 7, 2015 ⁽¹⁴⁾	—	—	—	—	642,000	642,000
	Options	1,141,000	July 29, 2016 ⁽²⁾	—	5.558	—	—	—	1,141,000
	RSUs	380,000	July 29, 2016 ⁽¹⁴⁾	—	—	—	—	95,000	285,000
	RSUs	—	June 14, 2017 ⁽¹⁴⁾	4,854,000	—	—	—	—	4,854,000
Employees									
Employees	Options	18,149,500	September 7, 2015 ⁽³⁾	—	5.184	—	2,955,750	—	15,193,750
	RSUs	6,804,400	September 7, 2015 ⁽¹⁴⁾	—	—	—	1,193,750	1,899,250	3,711,400
	Options	1,980,000	October 20, 2015 ⁽⁴⁾	—	5.550	—	947,000	—	1,033,000
	RSUs	2,294,700	October 20, 2015 ⁽¹⁴⁾	—	—	—	379,000	379,000	1,536,700
	Options	4,264,000	April 28, 2016 ⁽⁵⁾	—	5.320	—	699,000	—	3,565,000
	RSUs	10,124,955	April 28, 2016 ⁽¹⁴⁾	—	—	—	2,824,195	1,956,360	5,344,400
	Options	17,096,600	July 29, 2016 ⁽⁶⁾	—	5.558	—	1,778,000	—	15,318,600
	RSUs	12,882,900	July 29, 2016 ⁽¹⁴⁾	—	—	—	1,341,800	2,834,700	8,706,400
	Options	1,783,000	October 11, 2016 ⁽⁷⁾	—	4.416	—	371,000	—	1,412,000
	RSUs	2,250,300	October 11, 2016 ⁽¹⁴⁾	—	—	—	456,600	730,500	1,063,200
	RSUs	1,750,200	November 23, 2016 ⁽¹⁴⁾	—	—	—	—	559,000	1,191,200
	Options	6,680,000	February 2, 2017 ^{(8)&(9)}	—	3.626	—	1,579,000	—	5,101,000
	RSUs	4,176,000	February 2, 2017 ⁽¹⁴⁾	—	—	—	1,022,000	58,000	3,096,000
	Options	116,000	February 22, 2017 ^{(9)&(10)}	—	3.610	—	—	—	116,000
	RSUs	2,967,000	February 22, 2017 ⁽¹⁴⁾	—	—	—	—	856,600	2,110,400
	Options	—	June 14, 2017 ^{(11)&(12)}	3,523,000	3.902	—	—	—	3,523,000
	RSUs	—	June 14, 2017 ⁽¹⁴⁾	28,445,000	—	—	1,670,000	308,800	26,466,200
	Options	—	August 3, 2017 ⁽¹³⁾	14,797,000	3.686	—	253,000	—	14,544,000
	RSUs	—	August 3, 2017 ⁽¹⁴⁾	8,475,200	—	—	126,000	—	8,349,200



ADDITIONAL INFORMATION

Notes:

- (1) The options granted to Mr. WANG Lei on September 7, 2015 shall vest in accordance with vesting schedule as follows:
 - (i) as to 50% of the options granted shall vest on April 30, 2017;
 - (ii) as to 25% of the options granted shall vest on April 30, 2018; and
 - (iii) as to 25% of the options granted shall vest on April 30, 2019.
- (2) The closing price of HK\$5.39 per Share is stated in the daily quotation sheets issued by the Stock Exchange on the date of grant, and the options granted to Mr. WANG Lei on July 29, 2016 shall vest in 4 tranches of 25% each on July 31 of 2017, 2018, 2019 and 2020, respectively.
- (3) The options granted on September 7, 2015 to the employees shall vest on or before October 10, 2019.
- (4) The options granted on October 20, 2015 shall vest in accordance with vesting schedule as follows:
 - (i) as to 50% of the options granted shall vest on October 10, 2017;
 - (ii) as to 25% of the options granted shall vest on October 10, 2018; and
 - (iii) as to 25% of the options granted shall vest on October 10, 2019.
- (5) The closing price of HK\$5.32 per Share is stated in the daily quotation sheets issued by the Stock Exchange on the date of grant, and the options granted on April 28, 2016 shall vest on or before April 30, 2020.
- (6) The closing price of HK\$5.39 per Share is stated in the daily quotation sheets issued by the Stock Exchange on the date of grant, and the options granted on July 29, 2016 to the employees shall vest on or before July 31, 2020.
- (7) The closing price of HK\$4.31 per Share is stated in the daily quotation sheets issued by the Stock Exchange on the date of grant, and the options granted on October 11, 2016 shall vest on or before October 10, 2020.
- (8) The closing price of HK\$3.57 per Share is stated in the daily quotation sheets issued by the Stock Exchange on the date of grant.
- (9) The options granted on February 2, 2017 and February 22, 2017 respectively shall vest in accordance with vesting schedule as follows:
 - (i) as to 50% of the options granted shall vest on January 21, 2019;
 - (ii) as to 25% of the options granted shall vest on January 31, 2020; and
 - (iii) as to 25% of the options granted shall vest on January 31, 2021.
- (10) The closing price of HK\$3.61 per Share is stated in the daily quotation sheets issued by the Stock Exchange on the date of grant.

- (11) The options granted on June 14, 2017 shall vest in accordance with vesting schedule as follows:
- (i) as to 50% of the options granted shall vest on April 30, 2019;
 - (ii) as to 25% of the options granted shall vest on April 30, 2020; and
 - (iii) as to 25% of the options granted shall vest on April 30, 2021.
- (12) The closing price of HK\$3.80 per Share is stated in the daily quotation sheets issued by the Stock Exchange on the date of grant.
- (13) The closing price of HK\$3.57 per Share is stated in the daily quotation sheets issued by the Stock Exchange on the date of grant, and the options granted on August 3, 2017 to the employees shall vest on or before July 31, 2021.
- (14) All the RSUs granted shall vest in the grantees within four years from the date of grant.

The Company estimated the fair value of its share options using the binomial model, which requires the Group to make estimates about inputs, such as expected volatility, expected dividend yield, exercise multiple, risk-free interest rate and expected forfeiture rate, and hence such estimate is subject to subjectivity and uncertainty. For the accounting policy adopted for the Share Awards and the estimated fair value of the options granted during the six months ended September 30, 2016 and 2017, respectively, please refer to note 2.4 to the Group's consolidated financial statements for the year ended March 31, 2017 and Note 20 to the condensed consolidated financial statements for the six months ended September 30, 2017.

DIRECTORS' INTERESTS IN CONTRACTS

Save as disclosed under the section titled "Connected Transactions" below, no Director had a material interest, either directly or indirectly, in any contract of significance to the business of the Group to which the Company, its holding company, or any of its subsidiaries or fellow subsidiaries was a party during the period under review.

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at September 30, 2017, the interests and short positions of the Directors and chief executive in the share capital and underlying shares of the Company or its associated corporations (within the meaning of Part XV of SFO, as recorded in the register required to be kept by the Company pursuant to section 352 of the Securities and Futures Ordinance (the "SFO"), or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers, were as follows:

Long positions in shares and underlying shares of the Company

Name of Director	Nature of interest	Number of ordinary shares and underlying shares held, capacity and nature of interest	
		Total interest in shares	Percentage of the Company's share capital
Mr. Wang Lei	Beneficial Owner and Equity derivative interests (Note)	15,150,000	0.16%
Mr. Wu Yongming	Beneficial Owner	1,262,000	0.01%

Note: Subject to vesting, Mr. WANG Lei is interested in 737,000 ordinary shares and 14,413,000 shares underlying the 8,632,000 options and 5,781,000 RSUs granted to him in accordance with the Share Award Scheme adopted by the Company at the special general meeting held on November 24, 2014.

Long positions in shares and underlying shares of Alibaba Holding, an associated corporation of the Company within the meaning of Part XV of the SFO

Name of Director	Nature of interest	Number of shares/ underlying shares held	Approximate percentage of issued shares of associated corporation
Mr. WANG Lei	Beneficial, equity derivative interests and interests of spouse ⁽¹⁾	60,538	0.00%
	Beneficiary of a trust ⁽²⁾	20,000	0.00%
Mr. TSAI Chung, Joseph	Beneficial, equity derivative interests and interests of spouse ⁽³⁾	1,827,964	0.07%
	Interests in controlled corporation and other interests ⁽⁴⁾	56,729,130	2.21%
	Founder of a discretionary trust ⁽⁵⁾	6,482,293	0.25%
Ms. HUANG Aizhu	Beneficial and equity derivative interests ⁽⁶⁾	94,211	0.00%
Mr. KANG Kai	Beneficial and equity derivative interest ⁽⁷⁾	15,423	0.00%
Mr. WU Yongming	Beneficial and interests of spouse ⁽⁸⁾	231,017	0.01%
	Interests in controlled corporation ⁽⁹⁾	200,000	0.01%
	Founder of a discretionary trust ⁽¹⁰⁾	6,813,690	0.27%
Mr. YAN Xuan	Beneficial interest	3,000	0.00%

Notes:

- (1) It represents 30,560 ordinary shares or underlying ordinary shares and 26,250 restricted share units beneficially held by Mr. WANG Lei and 3,728 ordinary shares or underlying shares and restricted share units held by his spouse.
- (2) It represents 20,000 ordinary shares or underlying ordinary shares held by a private trust whereby Mr. WANG Lei and his family are beneficiaries.
- (3) It represents 1,588,797 ordinary shares and 79,167 restricted share units beneficially held by Mr. TSAI Chung, Joseph and 160,000 ordinary shares held by his spouse.
- (4) It represents the sum of 20,605,952 ordinary shares or underlying ordinary shares directly or indirectly held by Parufam Limited (of which Mr. TSAI Chung, Joseph is a director and has been delegated sole voting and disposition power), 21,123,178 ordinary shares held by PMH Holding Limited (of which Mr. TSAI Chung, Joseph is the sole director), and 15,000,000 ordinary shares held by APN Ltd. (in which Mr. TSAI Chung, Joseph holds 30% equity interest and has been granted a revocable proxy to vote 15,000,000 ordinary shares owned by APN Ltd.).
- (5) It represents the 6,482,293 ordinary shares and/or options held by Joe and Clara Tsai Foundation Limited (whereby Mr. TSAI Chung, Joseph is the "founder" of the trust within the meaning of the SFO).
- (6) It represents 60,836 ordinary shares or underlying ordinary shares and 33,375 restricted share units beneficially held by Ms. HUANG Aizhu.
- (7) It represents 4,673 ordinary shares or underlying ordinary shares and 10,750 restricted share units beneficially held by Mr. KANG Kai.
- (8) It represents 31,017 ordinary shares held by Mr. WU Yongming, and 200,000 ordinary shares held by his spouse.

ADDITIONAL INFORMATION

- (9) It represents 200,000 ordinary shares or underlying ordinary shares held by Plus Force Enterprise Ltd. (which is wholly-owned by Mr. WU Yongming).
- (10) It represents 6,813,690 ordinary shares or underlying ordinary shares held by Mr. WU Yongming through two private trusts whereby he is the founder of the discretionary trusts.

Save as disclosed above, as at September 30, 2017, none of the Directors and chief executive had registered an interest or short position in the shares and underlying shares of the Company or any of its associated corporations that was required to be recorded pursuant to section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers.

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS OR SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at September 30, 2017, the following interests and short positions of 5% or more of the share capital and share options of the Company were recorded in the register of interests required to be kept by the Company pursuant to section 336 of the SFO:

Long positions:

Name	Notes	Capacity and nature of interest	Number of shares/ underlying shares	% of the issued share capital of the Company
Perfect Advance Holding Limited	(1)	Beneficial owner	4,420,628,008	47.13%
Alibaba Group Holding Limited	(1)	Interest of controlled corporation	5,608,128,008	59.79%
Alibaba Investment Limited	(1)	Interest of controlled corporation	4,420,628,008	47.13%
Innovare Tech Limited	(1)	Persons acting in concert	4,420,628,008	47.13%
Yunfeng Fund II, L.P.	(1)	Persons acting in concert	4,420,628,008	47.13%
Yunfeng Investment GP II, Ltd.	(1)	Interest of controlled corporation	4,420,628,008	47.13%
Yunfeng Investment II, L.P.	(1)	Interest of controlled corporation	4,420,628,008	47.13%
Mr. Yu Feng	(1)	Interest of controlled corporation	4,420,628,008	47.13%
Mr. Ma Yun	(1)	Interest of controlled corporation	4,420,628,008	47.13%
Ali JK Nutritional Products Holding Limited	(1)	Beneficial owner	1,187,500,000	12.66%
Uni-Tech International Group Limited	(2)	Beneficial owner	777,484,030	8.29%
21CN Corporation	(2)	Interest of controlled corporation	777,484,030	8.29%
Pollon Internet Corporation	(2)	Interest of controlled corporation	777,484,030	8.29%
Ms. Chen Xiao Ying	(2)	Interest of controlled corporation	777,484,030	8.29%

Notes:

- (1) Perfect Advance Holding Limited (“**Perfect Advance**”) holds 4,420,628,008 shares.

Perfect Advance is owned by Alibaba Investment Limited (“**AIL**”) as to 70.21% and Innovare Tech Limited (“**Innovare**”) as to 29.79%. Perfect Advance is a party to the shareholders agreement dated April 30, 2014 entered into with AIL and Innovare which constitutes a concert party agreement for the purpose of section 317(1)(a) of the SFO. (Please refer to the circular of the Company dated March 21, 2014 for the details of the said shareholders agreement.)

AIL is wholly-owned by Alibaba Holding. Innovare is wholly controlled by Yunfeng Fund II, L.P., which is a direct wholly-owned subsidiary of Yunfeng Investment II, L.P. and an indirect wholly-owned subsidiary of Yunfeng Investment GP II, Ltd.. Yunfeng Investment GP II, Ltd. is owned by Mr. Ma Yun as to 40% and Mr. Yu Feng as to 60%. Accordingly, each of Yunfeng Fund II, L.P., Yunfeng Investment II, L.P., Yunfeng Investment GP II, Ltd., Mr. Ma Yun and Mr. Yu Feng is also deemed to have an interest in the 4,420,628,008 shares via Perfect Advance within the meaning of Part XV of the SFO.

Ali JK Nutritional Products Holding Limited (“**Ali JK**”) holds 1,187,500,000 shares. Ali JK is owned by Alibaba Holding as to 100%. Therefore Alibaba Holding is deemed to have an interest in an aggregate of 5,608,128,008 shares via Perfect Advance and Ali JK within the meaning of Part XV of the SFO.

- (2) Uni-Tech International Group Limited holds 777,484,030 shares and is wholly-owned by 21CN Corporation. 21CN Corporation is wholly-owned by Pollon Internet Corporation, which is wholly-owned by Ms. Chen Xiao Ying.

Save as disclosed above, as at September 30, 2017, no person, other than the Directors and chief executive of the Company, whose interests are set out in the section titled “Directors’ and Chief Executive’s Interests and Short Positions in Shares and Underlying Shares” above, had registered an interest or short position in the shares or underlying shares of the Company that was required to be recorded pursuant to section 336 of the SFO.

CONNECTED TRANSACTIONS

(a) Continuing Connected Transaction — Cloud Computing Services Agreement

On March 13, 2017, Alibaba Health Technology (China) Company Limited* (阿里健康科技(中國)有限公司) (“**Alibaba Health Technology (China)**”), an indirect wholly-owned subsidiary of the Company, entered into a third renewed Cloud Computing Services Agreement (the “**Third Renewed Agreement**”) with Alibaba Cloud Computing Ltd.* (阿里雲計算有限公司) (“**Alibaba Cloud**”). Pursuant to the Third Renewed Agreement, Alibaba Cloud agreed to provide certain cloud computing services to the Group for a term of one year from April 1, 2017 to March 31, 2018, with expected total fees payable by Alibaba Health Technology (China) to Alibaba Cloud being not more than HK\$7 million. The purpose of the transaction is to acquire technology input on cloud computing or other data processing solutions for processing big data in order to maintain a stable and sophisticated system to cater for real-time access to the Group’s Ma Shang Fang Xin tracking platform by customers.



ADDITIONAL INFORMATION

Perfect Advance is a substantial shareholder and a connected person of the Company. Alibaba Holding is the ultimate majority shareholder of Perfect Advance and Alibaba Cloud is a member of Alibaba Group. Accordingly, Alibaba Cloud is also a connected person of the Company and the transactions contemplated under the Third Renewed Agreement constitute continuing connected transactions of the Company in accordance with the Listing Rules. During the six months ended September 30, 2017, the aggregate value of services fees charged by Alibaba Cloud under the Third Renewed Agreement was approximately of RMB3.0 million (2016: RMB3.1 million).

(b) Continuing Connected Transaction – Tmall Services Agreement with Alibaba Health Technology (China)

On March 10, 2017, Alibaba Health Technology (China) entered into a service agreement (the “**Service Agreement**”) with Zhejiang Tmall Technology Co., Ltd* (浙江天貓技術有限公司) (“**Tmall Technology**”) and Zhejiang Tmall Network Co., Ltd* (浙江天貓網絡有限公司) (“**Tmall Network**”, together with Tmall Technology, the “**Tmall Entities**”) to, renew the original service agreement entered into by the same parties on August 24, 2016 with substantially the same key terms for one year until March 31, 2018. Pursuant to the Service Agreement, Alibaba Health Technology (China) agreed to provide to the Tmall Entities certain outsourced and value-added services in relation to certain categories of products or services sold on or offered on Tmall for the payment of fees. The Tmall Entities are members of Alibaba Group. Accordingly, the Tmall Entities are connected persons of the Group.

The transactions contemplated under the Services Agreement constitute non-exempt continuing connected transactions of the Company, and have been approved by independent shareholders of the Company at the special general meeting held on March 30, 2017. The proposed annual cap in respect of the service fees payable to the Group during the term of the Services Agreement is RMB110 million. For the period from the effective date of the Services Agreement, being March 31, 2017, till September 30, 2017, the aggregate service fees received by the Group under the Services Agreement was approximately RMB49.6 million.

(c) Continuing Connected Transaction – Services Framework Agreement

On December 31, 2016, the Company (for itself and on behalf of its subsidiaries) entered into the services framework agreement with Alibaba.com China Limited (阿里巴巴網絡中國有限公司) and Taobao China Holding Limited (淘寶中國控股有限公司) (“**Taobao China**”) (for themselves and on behalf of their subsidiaries) (the “**Services Framework Agreement**”), pursuant to which Alibaba (China) Technology Co., Ltd.* (阿里巴巴(中國)網絡技術有限公司), Hangzhou Alibaba Advertising Co., Ltd.* (杭州阿里巴巴廣告有限公司), Taobao China, the Tmall Entities and their respective affiliates (the “**AGH Service Group**”) will provide various services to the Group, including but not limited to internet information related software technical services and secondary domain name services, and the Group will pay the service fees calculated in accordance with the standard terms and conditions as amended and published on the respective online sales platforms operated by the respective entities from time to time. The Services Framework Agreement commenced from March 11, 2017 and is effective until March 31, 2018. It enables the Company to continue to market and sell products and services on online sales platforms operated by the respective parties and thus enable the Company to reach out to more customers and improve its understanding of their needs.

As Alibaba Holding is the ultimate majority shareholder of the Company and controls the AGH Service Group, each of the members of the AGH Service Group is a connected person of the Company. The transactions contemplated under the Services Framework Agreement constitute non-exempt continuing connected transactions of the Company, and have been approved by independent shareholders of the Company at the special general meeting held on March 10, 2017. The annual cap for the service fees payable by the Group under the Services Framework Agreement for the year ending March 31, 2018 is RMB60 million, and the actual amount of fees so incurred for the six months ended September 30, 2017 was RMB26.5 million.

(d) Continuing Connected Transactions — Agency Agreement

On June 28, 2017, Hangzhou Alimama Software Services Co., Ltd.* (杭州阿里媽媽軟件服務有限公司) (“**Alimama**”) and Alibaba Health (Hong Kong) Technology Company Limited (阿里健康(香港)科技有限公司) (“**Alibaba Health (HK)**”) entered into an agency agreement (the “**Renewed Agency Agreement**”) to renew the original agency agreement entered into between Alimama and Alibaba Health Technology (China) for a term of one year running retrospectively from April 1, 2017 to March 31, 2018. Pursuant to the Renewed Agency Agreement, Alibaba Health (HK) (for itself and on behalf of its subsidiaries), as the marketing agent, will refer contracted clients of Alibaba Health HK and its subsidiaries (the “**Alibaba Health Group**”) to purchase, and Alimama, as the marketing services provider, will provide to Alibaba Health Group’s contracted clients, various marketing and advertising services on the marketing and branding platforms provided by Alimama and/or its affiliated companies during the term of the Renewed Agency Agreement. The annual cap contemplated under the Renewed Agency Agreement covers the incentive fees to be received by the Alibaba Health Group from Alimama with regards to the marketing expenses to be incurred by or on behalf of its contracted clients. It is expected that the annual cap of the incentive fees to be received by Alibaba Health Group under the Renewed Agency Agreement for the year ending March 31, 2018 will be not more than RMB7 million, while no incentive fee was actually incurred for the six months ended September 30, 2017.

Perfect Advance is a substantial shareholder and a connected person of the Company. Alibaba Holding is the ultimate majority shareholder of Perfect Advance and Alimama is an indirect wholly-owned subsidiary of Alibaba Holding. Accordingly, Alimama is also a connected person of the Company and the transactions contemplated under the Renewed Agency Agreement constitute continuing connected transactions of the Company.

(e) Continuing Connected Transactions — Logistics Services Framework Agreement

On June 28, 2017, the Company (for itself and on behalf of its subsidiaries) entered into the logistics services framework agreement (the “**Logistics Services Framework Agreement**”) with Zhejiang Cainiao Supply Chain Management Co., Ltd.* (浙江菜鳥供應鏈管理有限公司) (“**Zhejiang Cainiao**”) (for itself and on behalf of its affiliates), pursuant to which Cainiao Smart Logistics Network Limited and its subsidiaries (the “**Cainiao Group**”) will provide various logistics services and the Group will pay the service fees. The term of the Logistics Services Framework Agreement is from April 1, 2017 to March 31, 2018. The Company expects that the total service fees to be paid by the Group to the Cainiao Group under the Logistics Services Framework Agreement for the year ending March 31, 2018 will be not more than RMB23 million, while the actual amount incurred for the six months ended September 30, 2017 was approximately RMB10.3 million.

Perfect Advance is a substantial shareholder of the Company. As Zhejiang Cainiao is an associate of Perfect Advance, each of the members of the Cainiao Group is a connected person of the Company. The transactions contemplated under the Logistics Services Framework Agreement between the Group and the Cainiao Group constitute continuing connected transactions of the Company.

(f) Continuing Connected Transactions — Shared Services Agreement

On July 3, 2017, the Company entered into the shared services agreement (the “**Shared Services Agreement**”) with Alibaba Holding, pursuant to which Alibaba Holding shall procure certain shared service providers, including Alibaba Holding and persons controlled by it, to provide to the Group certain shared services, including office premises sharing and support services, for a term of one year with retrospective effect from April 1, 2017 to March 31, 2018. Pursuant to the Shared Services Agreement, the total amount of fees payable by the Group to the shared service providers for the shared services for the year ending March 31, 2018 shall not be more than RMB23 million, while the actual amount incurred was approximately RMB9.3 million for the six months ended September 30, 2017.

Perfect Advance is a substantial shareholder and a connected person of the Company. Alibaba Holding is the ultimate majority shareholder of Perfect Advance. Accordingly, the transactions contemplated under the Shared Services Agreement constitute continuing connected transactions of the Company in accordance with the Listing Rules.

(g) Connected Transaction — Share Purchase Agreement and Continuing Connected Transactions — Framework Technical Services Agreement

On May 18, 2017, the Company entered into the share purchase agreement (the “**Share Purchase Agreement**”) with Ali JK Nutritional Products Holding Limited (the “**Vendor**”), a direct wholly-owned Subsidiary of Alibaba Holding, pursuant to which the Company will acquire a 100% equity interest in Ali JK Nutritional Products Limited, an offshore holding vehicle incorporated under the laws of the British Virgin Islands by the Vendor to hold the target business. The aggregate consideration is HK\$3,800,000,000 and was satisfied by the Company issuing 1,187,500,000 consideration shares to the Vendor at completion, which took place on June 30, 2017.

In connection with the transaction contemplated under the Share Purchase Agreement, the Tmall Entities and Hangzhou Hengping Information Technology Co., Ltd* (杭州衡平信息科技有限公司), an indirect wholly-owned subsidiary of the Vendor (the “WFOE”) entered into the framework technical services agreement (the “**Framework Technical Services Agreement**”) on May 18, 2017. Pursuant to the Framework Technical Services Agreement, the Tmall Entities will provide infrastructure technical support for the operation of Tmall.com to the WFOE for a service fee. Pursuant to the Framework Technical Services Agreement, the total amount of fees payable to the Tmall Entities shall not be more than RMB40 million, RMB65 million and RMB85 million for each of the years ending March 31, 2018, 2019 and 2020 respectively. The actual amount incurred up to September 30, 2017 was approximately RMB7.9 million.

As the Vendor is a direct wholly-owned subsidiary of Alibaba Holding, the ultimate majority shareholder of the Company, the Vendor is a connected person of the Company, and the transaction contemplated under the Share Purchase Agreement constituted a connected transaction of the Company. The Framework Technical Services Agreement and the transactions contemplated thereunder also constitute non-exempt continuing connected transactions of the Company. Independent shareholders of the Company approved the Share Purchase Agreement and the Framework Technical Services Agreement and the transactions contemplated thereunder at the special general meeting held on June 29, 2017. The term of the Framework Technical Services Agreement commenced on July 1, 2017 and will end on March 31, 2020, unless otherwise mutually agreed between the parties.

(h) Continuing connected transactions – Payment Services Framework Agreement

On September 20, 2017, the Company (for itself and on behalf of its subsidiaries) entered into the payment services framework agreement (the “**Payment Services Framework Agreement**”) with Alipay.com Co., Ltd.* (支付寶(中國)網絡技術有限公司) (“Alipay”), pursuant to which Alipay will provide the payment services and the Group will pay the service fees. The term of the Payment Services Framework Agreement is from September 20, 2017 to March 31, 2018.

Alipay is a wholly-owned subsidiary of Ant Small and Micro Financial Services Group Co., Ltd.* (浙江螞蟻小微金融服務集團股份有限公司) (“**Ant Financial**”), which, together with its subsidiaries, were confirmed as deemed connected persons of the Company by the Stock Exchange on July 10, 2017 under Rule 14A.19 of the Listing Rules. Accordingly, Alipay has been deemed as a connected person of the Company since July 10, 2017 and the transactions contemplated under the Payment Services Framework Agreement constitute continuing connected transactions for the Company. The Company expects that the total service fees to be paid by the Group to Alipay (i) under the individual service agreements entered into between the Group and Alipay for the provision of the payment services prior to the confirmation of Alipay as a deemed connected person of the Group; and (ii) under the Payment Services Framework Agreement for the period from July 10, 2017 to March 31, 2018 will not be more than RMB10 million. The actual amount of service fees for the six months ended September 30, 2017 was approximately RMB1.9 million.

* For identification purpose only

(i) Continuing connected transactions – Tracking Services Agreement

On September 26, 2017, Alibaba Health Technology (China), an indirect wholly-owned subsidiary of the Company, entered into the tracking services agreement (the “**Tracking Services Agreement**”) with Taobao China, pursuant to which Alibaba Health Technology (China) shall provide to Taobao China certain tracking services for a term commencing on September 26, 2017 and ending on August 31, 2018. Pursuant to the Tracking Services Agreement, the total amount of fees payable by Taobao China to Alibaba Health Technology (China) for the provision of the tracking services for the term shall not be more than RMB9.0 million.

Perfect Advance is a substantial shareholder and a connected person of the Company. Alibaba Holding is the ultimate majority shareholder of Perfect Advance and Taobao China is an indirect wholly-owned subsidiary of Alibaba Holding. Accordingly, Taobao China is a connected person of the Company and the transactions contemplated under the tracking services Agreement constitute continuing connected transactions of the Company in accordance with the Listing Rules.

As Mr. Wu Yongming, Mr. Tsai Chung, Joseph, Ms. Huang Aizhu and Mr. Kang Kai are employees of Alibaba Holding or its subsidiaries, each of these Directors is deemed or may be perceived to have a material interest in each of the above connected transaction/continuing connected transactions. Accordingly, they abstained from voting on the resolutions approving each of the above connected transaction/continuing connected transactions.

The Group has imposed internal control procedures to ensure that the continuing connected transactions are conducted in accordance with the pricing policies or mechanism under the relevant framework agreements. A specialized internal audit function has been set up to carry out independent appraisal of the adequacy and effectiveness of the internal control procedures and to review all the connected transactions. Any findings by the internal audit function have been provided to the Directors to assist them in performing the ongoing review of the continuing connected transactions.

INTERIM DIVIDEND

The Board resolved that no interim dividend be declared for the six months ended September 30, 2017 (September 30, 2016: Nil).

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended September 30, 2017, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities, except that a trustee of the Share Award Scheme purchased a total of 2,433,300 shares of the Company from the market to satisfy the Share Awards granted to connected employees of the Company upon vesting.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company strives to continuously attain and maintain high standards of corporate governance as it believes that effective corporate governance practices are fundamental to safeguarding the interests of its shareholders and other stakeholders, and to enhancing shareholder value.

In the opinion of the Board of the Company, throughout the six months ended September 30, 2017, the Company has complied with the code provisions (the "**Code Provisions**") set out in the Corporate Governance Code under Appendix 14 to the Listing Rules, except in respect of the following matter:

Code provision A.6.7 stipulates that independent non-executive directors and other non-executive directors of the Company should attend general meetings and develop a balanced understanding of the views of shareholders. Mr. Wu Yongming, Mr. Tsai Chung, Joseph, Ms. Huang Aizhu and Mr. Kang Kai, being non-executive directors of the Company, and Mr. Yan Xuan and Mr. Luo Tong, being independent non-executive directors of the Company were not able to attend the special general meeting of the Company held on June 29, 2017; and Mr. Wu Yongming, Mr. Tsai Chung, Joseph, Ms. Huang Aizhu and Mr. Kang Kai were not able to attend the annual general meeting of the Company held on July 26, 2017 due to conflicts of prior scheduled engagements with the meeting times. However, the Company has reported to the Directors on the items discussed at the general meetings and the feedback from the shareholders.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the model code as set out in Appendix 10 to the Listing Rules (the "**Model Code**") to regulate the dealings of directors of the Company in the Group's securities. In response to specific enquiries by the Company, all directors of the Company have confirmed that they have complied with the Model Code in their securities transactions throughout the six months ended September 30, 2017.

REVIEW OF INTERIM RESULTS

The unaudited condensed consolidated interim financial information of the Group for the six months ended September 30, 2017 has been reviewed by the audit committee of the Company and the Group's auditor, Messrs. Ernst & Young.

Hong Kong
November 15, 2017



Independent Review Report

To the board of directors of Alibaba Health Information Technology Limited

(Incorporated in Bermuda with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 31 to 60, which comprises the interim condensed consolidated statement of financial position of Alibaba Health Information Technology Limited (the “**Company**”) and its subsidiaries as at 30 September 2017 and the related interim condensed consolidated statement of profit or loss, interim condensed consolidated statement of comprehensive income, interim condensed consolidated statement of changes in equity and interim condensed consolidated statement of cash flows for the six-month period then ended, and explanatory notes. The Main Board Listing Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and Hong Kong Accounting Standard 34 “Interim Financial Reporting” (“**HKAS 34**”) issued by the Hong Kong Institute of Certified Public Accountants.

The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with HKAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with HKAS 34.

Ernst & Young

Certified Public Accountants

22/F, CITIC Tower

1 Tim Mei Avenue, Central

Hong Kong

15 November 2017

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended September 30, 2017

		Six months ended September 30,	
		2017 Unaudited RMB'000	2016 Unaudited RMB'000
	<i>Notes</i>		
REVENUE	3	889,731	55,027
Cost of revenue		(634,243)	(7,498)
Gross profit		255,488	47,529
Operating expenses			
Fulfillment	4	(146,850)	(821)
Sales and marketing expenses		(86,471)	(49,566)
Administrative expenses		(57,313)	(51,543)
Product development expenses		(61,377)	(50,441)
Other income and gains	5	17,244	6,143
Finance cost	6	(5,134)	(2,055)
Other expenses		(2,199)	(11,075)
Share of profits or losses of:			
A joint venture	7	3,017	4,478
Associates	8	(7,976)	2,574
LOSS BEFORE TAX	9	(91,571)	(104,777)
Income tax expense	10	(607)	(1,048)
LOSS FOR THE PERIOD		(92,178)	(105,825)
Attributable to:			
Owners of the parent		(90,911)	(102,398)
Non-controlling interests		(1,267)	(3,427)
		(92,178)	(105,825)
LOSS PER SHARE ATTRIBUTABLE TO OWNERS OF THE PARENT			
—Basic and diluted	12	RMB(1.07) cents	RMB(1.25) cents

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended September 30, 2017

	Six months ended September 30,	
	2017 Unaudited RMB'000	2016 Unaudited RMB'000
LOSS FOR THE PERIOD	<u>(92,178)</u>	<u>(105,825)</u>
Other comprehensive (loss)/income may be reclassified to profit or loss in subsequent periods:		
Translation from functional currency to presenting currency	<u>(20,861)</u>	<u>31,463</u>
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX	<u>(20,861)</u>	<u>31,463</u>
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	<u>(113,039)</u>	<u>(74,362)</u>
Attributable to:		
Owners of the parent	<u>(111,772)</u>	<u>(70,935)</u>
Non-controlling interests	<u>(1,267)</u>	<u>(3,427)</u>
	<u>(113,039)</u>	<u>(74,362)</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at September 30, 2017

	<i>Notes</i>	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
NON-CURRENT ASSETS			
Property and equipment		7,026	5,065
Goodwill	13	19,123	19,123
Investment in a joint venture		45,661	42,644
Investments in associates	14	851,564	524,801
Pledged deposit	15	—	222,848
Long-term receivables		55,126	54,304
Total non-current assets		978,500	868,785
CURRENT ASSETS			
Inventories		273,461	151,505
Trade receivables	16	66,107	38,501
Prepayments, deposits and other receivables		79,262	39,835
Financial assets at fair value through profit or loss		94,800	10,300
Restricted cash	15	2,268	914
Pledged deposit	15	265,115	—
Cash and cash equivalents		109,350	569,860
Total current assets		890,363	810,915
CURRENT LIABILITIES			
Interest-bearing bank borrowing	17	200,000	—
Trade payables	18	190,565	125,862
Other payables and accruals		352,749	189,462
Receipt in advance		55,429	38,148
Total current liabilities		798,743	353,472
NET CURRENT ASSETS		91,620	457,443
TOTAL ASSETS LESS CURRENT LIABILITIES		1,070,120	1,326,228

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at September 30, 2017

	<i>Notes</i>	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
NON-CURRENT LIABILITIES			
Interest-bearing bank borrowing	17	—	200,000
Deferred tax liability		6,951	6,566
Total non-current liabilities		6,951	206,566
Net assets		1,063,169	1,119,662
EQUITY			
Equity attributable to owners of the parent			
Share capital	19	82,781	72,481
Treasury shares	19	(5,191)	(91)
Reserves		1,044,989	1,105,446
Non-controlling interests		1,122,579	1,177,836
		(59,410)	(58,174)
Total equity		1,063,169	1,119,662

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended September 30, 2017

Attributable to owners of the parent													
	Share		Treasury shares	Capital reserve	Contributed surplus	Exchange fluctuation reserve	Employee share-based		General reserve	Accumulated losses	Total	Non-controlling interests	Total equity
	Share capital	premium account					compensation reserve	reserve					
Notes	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At April 1, 2016 (audited)	72,305	1,863,621	–	33,979	77,335	20,860	37,472	13,468	(897,680)	1,221,360	(66,089)	1,155,271	
Loss for the period	–	–	–	–	–	–	–	–	(102,398)	(102,398)	(3,427)	(105,825)	
Other comprehensive loss for the period:													
Translation from functional currency to presenting currency	–	–	–	–	–	31,463	–	–	–	31,463	–	31,463	
Total comprehensive loss for the period	–	–	–	–	–	31,463	–	–	(102,398)	(70,935)	(3,427)	(74,362)	
Share-based compensation expenses	20	–	–	–	–	–	56,488	–	–	56,488	–	56,488	
Exercise of share options	–	249	–	–	–	–	(79)	–	–	170	–	170	
Vested awarded shares transferred to employees	19	47	23,706	–	–	–	(23,753)	–	–	–	–	–	
Issue of shares	19	29	–	(29)	–	–	–	–	–	–	–	–	
At September 30, 2016 (unaudited)	72,381	1,887,576	(29)	33,979	77,335	52,323	70,128	13,468	(1,000,078)	1,207,083	(69,516)	1,137,567	

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended September 30, 2017

	Attributable to owners of the parent												Total equity
	Share capital	Share premium account	Treasury share	Merger reserve	Capital reserve	Contributed surplus	Exchange fluctuation reserve	Employee share-based compensation reserve	General reserve	Accumulated losses	Total	Non-controlling interests	
Notes	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At April 1, 2017 (audited)	72,481	1,907,220 [^]	(91)	-	25,037 [^]	77,335 [^]	83,410 [^]	104,282 [^]	13,468 [^]	(1,105,306) [^]	1,177,836	(58,174)	1,119,662
Loss for the period	-	-	-	-	-	-	-	-	-	(90,911)	(90,911)	(1,267)	(92,178)
Other comprehensive loss for the period:													
Translation from functional currency to presenting currency	-	-	-	-	-	-	(20,861)	-	-	-	(20,861)	-	(20,861)
Total comprehensive loss for the period	-	-	-	-	-	-	(20,861)	-	-	(90,911)	(111,772)	(1,267)	(113,039)
Issue of new shares for an acquisition under common control	23(b) 10,300	3,821,342	-	(3,828,605)	-	-	-	-	-	-	3,037	-	3,037
Purchase of shares by Share Award Scheme Trust	19 -	-	(7,790)	-	-	-	-	-	-	-	(7,790)	-	(7,790)
Share-based compensation expenses	20 -	-	-	-	-	-	-	57,736	-	-	57,736	-	57,736
Vested awarded shares transferred to employees	20 -	42,231	2,690	-	-	-	-	(44,921)	-	-	-	-	-
Transfer of share-based compensation reserve of options forfeited after vesting date	-	-	-	-	-	-	-	(4,918)	-	4,918	-	-	-
Deemed interest of an interest-free loan to a non-wholly owned subsidiary	-	-	-	-	(31)	-	-	-	-	-	(31)	31	-
Share of capital reserve of an associate	-	-	-	-	3,563	-	-	-	-	-	3,563	-	3,563
At September 30, 2017 (unaudited)	82,781	5,770,793 [^]	(5,191)	(3,828,605) [^]	28,569 [^]	77,335 [^]	62,549 [^]	112,179 [^]	13,468 [^]	(1,191,299) [^]	1,122,579	(59,410)	1,063,169

[^] These reserve accounts comprise the consolidated reserves of RMB1,044,989,000 (March 31, 2017: RMB1,105,446,000) in the interim condensed consolidated statement of financial position.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended September 30, 2017

	Notes	Six months ended September 30,	
		2017 Unaudited RMB'000	2016 Unaudited RMB'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Loss before tax		(91,571)	(104,777)
Adjustments for:			
Share of profit of a joint venture	7	(3,017)	(4,478)
Share of profits or losses of associates	8	7,976	(2,574)
Interest income	5	(6,004)	(5,900)
Fair value loss on financial assets at fair value through profit or loss	9	500	—
Gain on disposal of items of property and equipment	5	(1)	(17)
Finance cost	6	5,134	2,055
Depreciation	9	1,985	2,181
Impairment of trade receivables	9	—	1,340
Write-off of inventory	9	57	—
Foreign exchange difference, net		(13,229)	9,735
Share-based compensation expense	20	57,736	56,488
		(40,434)	(45,947)
Increase in trade receivables		(27,606)	(7,428)
(Increase)/decrease in prepayments, deposits and other receivables		(36,127)	2,121
Increase in inventories		(122,013)	(5,040)
Increase in trade payables		64,703	4,684
Increase/(decrease) in other payables and accruals		17,727	(6,015)
Decrease in deferred revenue		—	(40,542)
Increase/(decrease) in receipt in advance		17,281	(1,605)
Exchange differences		2,707	(2,100)
Cash used in operations		(123,762)	(101,872)
Interest received		2,340	2,673
Dividend received from investment in an associate		4,839	—
PRC taxes paid		(222)	(269)
Net cash flows used in operating activities		(116,805)	(99,468)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended September 30, 2017

	Six months ended September 30,	
	2017 Unaudited RMB'000	2016 Unaudited RMB'000
Net cash flows used in operating activities	(116,805)	(99,468)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of items of property and equipment	(3,957)	(461)
Purchase of financial assets at fair value through profit or loss	(85,000)	—
Proceeds from disposal of items of property and equipment	10	17
Decrease of non-pledged time deposits with original maturity of over three months when acquired	—	296,140
Increase in restricted cash	—	(346,865)
Increase in pledged deposits	(45,881)	—
Acquisition of subsidiaries	—	(19,675)
Capital injection in associates	(185,588)	(112,500)
Net cash flows used in investing activities	(320,416)	(183,344)
CASH FLOWS FROM FINANCING ACTIVITIES		
Purchase of shares by Share Award Scheme Trust	(7,790)	—
Proceeds from exercise of options	—	170
Interest-bearing bank borrowing	—	99,873
Interest paid	(5,162)	—
Net cash flows (used in)/generated from financing activities	(12,952)	100,043
NET DECREASE IN CASH AND CASH EQUIVALENTS	(450,173)	(182,769)
Cash and cash equivalents at beginning of period	569,860	714,418
Effect of foreign exchange rate changes	(10,337)	23,836
CASH AND CASH EQUIVALENTS AT END OF PERIOD	109,350	555,485

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended September 30, 2017

	Six months ended September 30,	
	2017	2016
	Unaudited	Unaudited
	RMB'000	RMB'000
<hr/>		
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS		
Cash and bank balances	61,338	62,986
Non-pledged deposits with original maturity of three months or less when acquired	48,012	492,499
Non-pledged time deposits with original maturity over three months and within twelve months when acquired	—	10,000
	<hr/>	<hr/>
Cash and cash equivalents as stated in the condensed consolidated statement of financial position	109,350	565,485
Non-pledged time deposits with original maturity over three months and within twelve months when acquired	—	(10,000)
	<hr/>	<hr/>
CASH AND CASH EQUIVALENTS AS STATED IN THE INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS	109,350	555,485
	<hr/> <hr/>	<hr/> <hr/>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

1 GENERAL INFORMATION

Alibaba Health Information Technology Limited (the “**Company**”) is incorporated in Bermuda as an exempted company with limited liability. Its shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The address of its registered office is at Canon’s Court, 22 Victoria Street, Hamilton HM12, Bermuda. The principal place of business of the Company in the People’s Republic of China (the “**PRC**”) is located at Building B, Hong Tai Dong Jie, Greenland Center, Chaoyang District, Beijing, the PRC.

The Company is an investment holding company. The Company and its subsidiaries (collectively, the “**Group**”) are primarily engaged in healthcare product sales and services, tracking services, and intelligent medicine and healthcare management services.

In the opinion of the directors, the Company’s immediate holding company is Perfect Advance Holding Limited (“**Perfect Advance**”), which is incorporated in the British Virgin Islands, and the ultimate holding company of the Company is Alibaba Group Holding Limited (“**Alibaba Holding**”, together with its subsidiaries, “**Alibaba Group**”).

2 BASIS OF PREPARATION AND PRINCIPAL ACCOUNTING POLICIES

2.1 Basis of preparation

The interim condensed consolidated financial statements for the six months ended September 30, 2017 have been prepared in accordance with Hong Kong Accounting Standard (“**HKAS**”) 34 “*Interim Financial Reporting*” issued by the Hong Kong Institute of Certified Public Accountants.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual financial statements for the year ended March 31, 2017.

Certain comparative amounts in interim condensed consolidated financial statement have also been reclassified to conform with current period’s presentation.

The Company has set up a trust (the “**Share Award Scheme Trust**”) for the purpose of purchasing, administering and holding the Company’s shares for the share award scheme adopted on November 24, 2014 (the “**Share Award Scheme**”, note 20). The Group has the power to govern the financial and operating policies of the Share Award Scheme Trust and derive benefits from the services of the employees who have been awarded the awarded shares through their continued employment with the Group. The assets and liabilities of the Share Award Scheme Trust are included in interim condensed consolidated statement of financial position and the shares held by the Share Award Scheme Trust are presented as a deduction in equity as shares held for the share award scheme.

2 BASIS OF PREPARATION AND PRINCIPAL ACCOUNTING POLICIES (continued)

2.1 Basis of preparation (continued)

The Company does not have legal ownership in the equity of certain entities. However, under certain contractual agreements (including power of attorney agreement, loan agreement, equity option agreement, equity interest pledge agreement and exclusive technical consulting and services agreement) entered into with the registered owners of the entity, the Company through its indirectly wholly-owned subsidiary controls the entity by way of controlling the voting rights, governing the financial and operating policies, appointing or removing the majority of the members of its controlling authorities, and casting the majority of votes at meetings of such authorities. In addition, such contractual agreements also transfer the risks and rewards of the entity to the Company and/or its indirectly owned subsidiary. As a result, the entity is treated as a subsidiary of the Company and its financial statements have been consolidated by the Company.

2.2 Significant accounting policies, new standards and amendments adopted by the Group

The accounting policies adopted in, and basis of, preparation of the interim condensed consolidated financial statements are the same as those used in the annual financial statements of the Group for the year ended March 31, 2017, except in relation to the following accounting policies:

Revenue recognition of e-commerce platform services

Given that the Group has started providing Blue Cap Health Food[^] e-commerce platform maintenance related software services to merchants on Tmall.com, the Group earns commissions from merchants when transactions are completed and settled on Tmall.com. Such commissions are determined as a percentage based on the value of Blue Cap Health Food being sold by the merchants. Revenue related to commissions is recognized in the condensed consolidated statement of profit or loss at the time when the underlying transaction is completed.

Merger accounting

As disclosed in note 23(b) to the interim condensed consolidated financial statements, a business combination under common control was effected during the current interim period, where the business acquired in the business combination and the Company are both ultimately controlled by Alibaba Holding ("Controlling Party"). The net assets of the combining entities are consolidated using the existing book values from the Controlling Party's perspective. No adjustments are made to reflect fair values, or recognise any new assets or liabilities as a result of the business combination under common control and no amount is recognised in respect of goodwill. The interim condensed consolidated statement of profit or loss and interim condensed consolidated statement of other comprehensive income, interim condensed consolidated statement of changes in equity and interim condensed consolidated statement of cash flows of the Group include the results and cash flows of the acquired business from the date when the acquiring company obtains control of the acquired business. No restatement was made for periods prior to the business combination under common control effected during the six months ended September 30, 2017.

[^] Blue Cap Health Food represents food products that are registered or filed, from time to time, with China Food and Drug Administration ("CFDA") as "health food" in accordance with the Health Food Registration and Filing Administrative Rules (《保健食品註冊與備案管理辦法》) and the Food Safety Law of the PRC (《中華人民共和國食品安全法》) (as such laws and regulations may be amended from time to time) and have obtained a health food ("Blue Cap") label with a unique registration or filing tracking number from the CFDA.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

2 BASIS OF PREPARATION AND PRINCIPAL ACCOUNTING POLICIES (continued)

2.2 Significant accounting policies, new standards and amendments adopted by the Group (continued)

The following new and revised Hong Kong Financial Reporting Standards (“HKFRSs”) (which include all Hong Kong Financial Reporting Standards, HKASs and Interpretations) that affect the Group and are adopted for the first time for the current period’s interim condensed consolidated financial statements.

Amendments to HKAS 7	<i>Disclosure Initiative</i>
Amendments to HKAS 12	<i>Recognition of Deferred Tax Assets for Unrealised Losses</i>
<i>Annual Improvements 2014-2016 Cycle</i>	Amendments to a number of HKFRSs

The adoption of the above HKFRSs has had no significant impact on the Group’s interim condensed consolidated financial statements.

3 REVENUE AND SEGMENT INFORMATION

The Group is primarily engaged in online and offline healthcare product sales, the provision of e-commerce platform services, which includes providing maintenance related software services to Blue Cap Health Food merchants on Tmall.com and providing outsourced and value-added services to Zhejiang Tmall Network Co., Ltd.* (浙江天貓網絡有限公司) and Zhejiang Tmall Technology Co., Ltd.* (浙江天貓技術有限公司, together with Zhejiang Tmall Network Co., Ltd.* hereinafter referred to as “Tmall Entities”), the provision of tracking services principally for the drug industry in the PRC, the construction of a medical services network and other innovative healthcare related services. Given that the chief operating decision maker of the Company considers that the Group’s business is operated and managed as a single segment, accordingly, no segment information is presented.

An analysis of revenue is as follows:

	Six months ended September 30,	
	2017 Unaudited RMB’000	2016 Unaudited RMB’000
Healthcare product sales	786,179	1,580
E-commerce platform services	66,610	3,074
Tracking services	9,437	48,983
Innovative healthcare related services and others	27,505	1,390
Total	<u>889,731</u>	<u>55,027</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

4 FULFILLMENT

Fulfillment includes warehousing, shipping, operating and customer services, which are associated with the Group's B2C online pharmacy business for over-the-counter drugs and other health related products.

5 OTHER INCOME AND GAINS

	Six months ended September 30,	
	2017 Unaudited RMB'000	2016 Unaudited RMB'000
Interest income	6,004	5,900
Gain on disposal of items of property and equipment	1	17
Foreign exchange difference, net	10,980	—
Others	259	226
Total	<u>17,244</u>	<u>6,143</u>

6 FINANCE COST

Finance cost is interest on bank borrowing of the Group.

7 SHARE OF PROFIT OF A JOINT VENTURE

The Group recorded share of profit from a 49%-owned joint venture, Beijing Honglian 95 Information Industries Company Limited* (北京鴻聯九五信息產業有限公司) ("HL95") for the six months ended September 30, 2017 and September 30, 2016.

8 SHARE OF PROFITS OR LOSSES OF ASSOCIATES

The Group recorded share of profits or losses from existing associates for the six months ended September 30, 2017 and share of profits or losses from newly acquired associates for the period from acquisition date to September 30, 2017.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

9 LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/(crediting):

	Six months ended September 30,	
	2017 Unaudited RMB'000	2016 Unaudited RMB'000
Cost of goods sold [^]	610,683	—
Cost of services provided [^] (excluding employee benefit expense and share-based compensation expenses)	18,815	6,661
Depreciation	1,985	2,181
Minimum lease payments under operating leases for office buildings	6,107	6,467
Fair value loss on financial asset at fair value through profit or loss [#]	500	—
Impairment of trade receivables [#]	—	1,340
Write-off of inventory [#]	57	—
Foreign exchange differences, net	(10,980)	9,735
Employee benefit expense (including directors' and chief executive's remuneration):		
Wages and salaries	89,395	54,665
Pension scheme contributions	6,710	4,461
Share-based compensation expense (note 20)	57,736	56,488
	153,841	115,614

[#] These items are included in "Other expenses" in the interim condensed consolidated statement of profit or loss.

[^] These items are included in "Cost of revenue" in the interim condensed consolidated statement of profit or loss.

10 INCOME TAX EXPENSE

	Six months ended September 30,	
	2017 Unaudited RMB'000	2016 Unaudited RMB'000
Current	222	269
Deferred	385	779
Total tax charge for the periods	607	1,048

Deferred income tax represents withholding tax on the distributable profits of the Group's associates and joint venture.

No provision for Hong Kong profits tax has been made for the six months ended September 30, 2017 and September 30, 2016 as the Group did not generate any assessable profits arising in Hong Kong.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

10 INCOME TAX EXPENSE (continued)

In general, the PRC subsidiaries of the Company are subject to the PRC corporate income tax rate of 25% except for two PRC subsidiaries which are entitled to a preferential tax rate of 15%.

11 DIVIDENDS

No dividend is proposed by the Board for the six months ended September 30, 2017 (six months ended September 30, 2016: Nil).

12 LOSS PER SHARE ATTRIBUTABLE TO OWNERS OF THE PARENT

The calculation of the basic loss per share amount is based on the loss for the period attributable to owners of the parent, and the weighted average number of ordinary shares of approximately 8,487,287,000 in issue during the period (for the six months ended September 30, 2016: 8,174,602,000).

No adjustment has been made to the basic loss per share amounts presented for the six months ended September 30, 2017 and September 30, 2016 in respect of a dilution, as the impact of the share options and restricted share units outstanding had an anti-dilutive effect on the loss per share amounts presented.

13 GOODWILL

	<i>Note</i>	Six months ended September 30,	
		2017 RMB'000 Unaudited	2016 RMB'000 Audited
Cost and net carrying amount at April 1		19,123	—
Acquisition of subsidiaries	<i>23(a)</i>	<u>—</u>	<u>19,123</u>
Cost and net carrying amount at September 30		<u>19,123</u>	<u>19,123</u>

14 INVESTMENTS IN ASSOCIATES

		September 30, 2017 RMB'000 Unaudited	March 31, 2017 RMB'000 Audited
Share of net assets		368,345	230,080
Goodwill on acquisition		<u>483,219</u>	<u>294,721</u>
		<u>851,564</u>	<u>524,801</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

14 INVESTMENTS IN ASSOCIATES (continued)

Note i: On May 19, 2017, Hongyun Jiukang Data Technology (Beijing) Co., Ltd.* (弘云久康數據技術(北京)有限公司) (“**Hongyun Jiukang**”), a company controlled by the Group, entered into a capital injection agreement with Jiahemeikang (Beijing) Technology Co., Ltd.* (嘉和美康(北京)科技股份有限公司) (“**Jiahe**”), a company established in the PRC with limited liability, and shareholders of Jiahe (the “**Original Shareholders**”), pursuant to which Hongyun Jiukang shall inject RMB291,176,470 in cash to Jiahe, of which approximately RMB15,045,882 will be contributed to Jiahe’s registered capital, and the remaining amount will be contributed to its capital reserve. Upon completion of the transaction on May 19, 2017, Jiahe was held as to 85% by Original Shareholders and 15% by Hongyun Jiukang, respectively.

A cash consideration of RMB145,588,235 was paid on May 23, 2017, while the remaining RMB145,588,235 was included in other payables and accruals as at September 30, 2017 and shall be paid at the earlier of June 30, 2018 and the day before the accounting reference date of the audited financial statements as determined by Jiahe for the purpose of future listing disclosures.

Note ii: On May 19, 2017, Hongyun Jiukang entered into a capital injection agreement with Jiahe and Beijing Jiameizaixian Technology Co., Ltd.* (北京嘉美在線科技有限公司) (“**Jiamei**”), which was established in the PRC with limited liability, pursuant to which Hongyun Jiukang shall inject RMB40,000,000 in cash to Jiamei, of which approximately RMB36,654,545 will be contributed to Jiamei’s registered capital, and the remaining amount will be contributed to its capital reserve. Upon completion of the transaction on July 19, 2017, Jiamei was held as to 55% by Jiahe and 45% by Hongyun Jiukang, respectively.

A cash consideration of RMB40,000,000 was fully paid by Hongyun Jiukang on June 21, 2017.

15 RESTRICTED CASH AND PLEDGED DEPOSITS

	September 30, 2017 RMB'000 Unaudited	March 31, 2017 RMB'000 Audited
Pledged deposit for bank loans:		
Non-current portion	—	222,848
Current portion	220,500	—
Pledge deposits for banking facility	44,615	—
Restricted cash	2,268	914
	267,383	223,762

16 TRADE RECEIVABLES

	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
Trade receivables	91,510	63,904
Impairment	(25,403)	(25,403)
	66,107	38,501

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

16 TRADE RECEIVABLES (continued)

The Group's trading terms with some of its customers are on credit. The Group provides credit periods from 30 to 90 days. Trade receivables are settled in accordance with the terms of the respective contracts. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

An aging analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of provisions, is as follows:

	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
Within 3 months	59,826	38,501
3 to 12 months	6,281	—
	66,107	38,501

17 INTEREST-BEARING BANK BORROWING

	September 30, 2017 Unaudited			March 31, 2017 Audited		
	Effective interest rate (%)	Maturity	RMB'000	Effective interest rate (%)	Maturity	RMB'000
Non-current						
Bank loan-secured	—	—	—	5.05	April 26, 2018	100,000
Bank loan-secured	—	—	—	5.05	October 10, 2018	100,000
			<u>—</u>			<u>200,000</u>
Current						
Bank loan-secured	5.05	April 26, 2018	100,000	—	—	—
Bank loan-secured	5.05	October 10, 2018	100,000[#]	—	—	—
			<u>200,000</u>			<u>—</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

17 INTEREST-BEARING BANK BORROWING (continued)

	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
Analysed into:		
Bank loans repayable:		
In the first year	200,000	—
In the second year	—	200,000
	200,000	200,000

The bank loan of RMB100 million was classified in current liability because the repayment of the loan was planned as of September 30, 2017 and made in October 2017.

18 TRADE PAYABLES

An aging analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
Within 3 months	188,828	125,079
3 to 12 months	1,680	4
Over 12 months	57	779
	190,565	125,862

The trade payables are non-interest-bearing and are normally settled on terms from 30 to 90 days.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

19 SHARE CAPITAL

Shares

	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
Authorised: 15,000,000,000 (March 31, 2017: 10,000,000,000) ordinary shares of HK\$0.01 each	128,040	85,360
Issued and fully paid: 9,380,236,918 (March 31, 2017: 8,192,736,918) ordinary shares of HK\$0.01 each	82,781	72,481
	Number of shares in issue	Treasury shares
	<i>RMB'000</i>	<i>RMB'000</i>
Ordinary shares of HK\$0.01 each		
— At April 1, 2016 (audited)	8,172,644,639	—
— Exercise of share options (unaudited) (Note a)	38,000	—
— Vested awarded shares transferred to employees (unaudited) (Note b)	5,465,954	—
— Issue of shares (unaudited) (Note c)	3,351,915	(29)
— At September 30, 2016 (unaudited)	<u>8,181,500,508</u>	<u>(29)</u>
— At April 1, 2017 (audited)	8,192,736,918	(91)
— Purchase of shares by Share Award Scheme Trust (unaudited) (Note d)	—	(7,790)
— Vested awarded shares transferred to employees (unaudited) (Note e)	—	2,690
— Issue of shares (unaudited) (Note f)	1,187,500,000	—
— At September 30, 2017 (unaudited)	<u>9,380,236,918</u>	<u>(5,191)</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

19 SHARE CAPITAL (continued)

- Note a:* On June 10, 2016 and July 19, 2016, 38,000 shares of HK\$0.01 each were issued at the price of HK\$5.184 per share upon exercise of share options by the option holders.
- Note b:* On April 21, 2016 and July 19, 2016, 5,465,954 shares of HK\$0.01 each were issued and transferred to employees upon vesting of restricted share units.
- Note c:* On August 24, 2016, 3,351,915 shares of HK\$0.01 each were issued for restricted share units to be vested on October 10, 2016.
- Note d:* In June 2017 and September 2017, a total of 2,433,300 ordinary shares were purchased from the market at a total consideration of HK\$9,174,000 (approximately to RMB7,790,000) for restricted share units vested on July 31, and October 10, 2017.
- Note e:* On April 30, 2017 and July 31, 2017, a total of 10,319,210 treasury shares were transferred to owners of vested restricted share units.
- Note f:* On June 30, 2017, 1,187.5 million shares of HK\$0.01 each were issued to a related company for the business combination under common control. Please refer to note 23(b) for further details.

20 SHARE-BASED COMPENSATION COSTS

Share award scheme

On November 24, 2014 (the “**Adoption Date**”), the Group adopted a share award scheme (the “**Share Award Scheme**”) for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group’s operations. An award (“**Award**”) granted under the Share Award Scheme may either take the form of a restricted share unit (“**RSU**”), being a contingent right to receive shares of the Company which are awarded under the Share Award Scheme or an option (“**Option**”) to subscribe for or acquire shares of the Company which are granted under the Share Award Scheme.

The total number of shares in respect of which Awards may be granted under the Share Award Scheme and any other share award schemes of the Company shall not exceed 3% of the shares in issue as at the Adoption Date (the “**Scheme Mandate Limit**”), or 3% of the shares in issue as at the new approval date of the renewed Scheme Mandate Limit.

The Awards do not confer rights on the holders to dividends or to vote at shareholders’ meetings.

Any grant of RSUs to any connected person of the Company and the issue and allotment of shares upon vesting of such RSUs will constitute a connected transaction (as defined in Chapter 14A of the Listing Rules) of the Company and shall therefore be subject to compliance with Chapter 14A of the Listing Rules (unless an exemption applies).

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

20 SHARE-BASED COMPENSATION COSTS (continued)

Share award scheme (continued)

Movements in the number of units of Awards granted under the Share Award Scheme during the current period and their related weighted average fair values are as follows:

	Weighted average exercise price of options <i>HK\$ per share</i>	Number of options <i>'000</i>	Number of RSUs <i>'000</i>
Outstanding at April 1, 2016 (audited)	5.21	32,185	19,344
Granted during the period	5.51	27,171	31,839
Forfeited during the period	5.26	(4,755)	(4,658)
Exercised or issued during the period	5.18	(38)	(5,466)
Outstanding at September 30, 2016 (unaudited)	<u>5.35</u>	<u>54,563</u>	<u>41,059</u>
Average fair value per option/RSU at September 30, 2016 (unaudited)		RMB2.37	RMB5.05
Outstanding at April 1, 2017 (audited)	5.12	58,701	44,914
Granted during the period	3.73	18,320	41,774
Forfeited during the period	4.95	(8,583)	(9,013)
Issued during the period	—	—	(10,319)
Outstanding at September 30, 2017 (unaudited)	<u>4.77</u>	<u>68,438</u>	<u>67,356</u>
Average fair value per option/RSU at September 30, 2017 (unaudited)		RMB2.09	RMB3.63

For options outstanding at the end of the current reporting period, the exercise prices range from HK\$3.610 to HK\$5.558. The exercise period of the options is from the vesting date to 10 years from the grant date. As at September 30, 2017, the remaining vesting periods for the options and RSUs granted range from 1 month to 46 months.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

20 SHARE-BASED COMPENSATION EXPENSE (continued)

Share award scheme (continued)

The fair value of options granted during the six months ended September 30, 2017 and September 30, 2016 was estimated as at the date of grant, using a binomial model, taking into account the terms and conditions upon which the options were granted. The following table lists the inputs to the model used:

	Six months ended September 30,	
	2017 Unaudited	2016 Unaudited
Fair value of the Company's shares at the grant date	HK\$3.57~HK\$3.80	HK\$5.32~HK\$5.39
Expected volatility (%)	65	70
Expected dividend (%)	0.00	0.00
Exercise multiple	2.2	2.2~2.8
Exercise price	HK\$3.686~HK\$3.902	HK\$5.320~HK\$5.558
Risk-free interest rate (%)	1.15	0.96~1.31
Forfeiture rate (%)	20~30	20~30

The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.

The fair value of the RSUs granted during the six months ended September 30, 2017 and September 30, 2016 was determined based on the market value of the Company's shares at the respective grant dates.

20 SHARE-BASED COMPENSATION EXPENSE (continued)

Share award scheme (continued)

Total share-based compensation expenses recorded by the Group under the Share Award Scheme are as follows:

	Six months ended September 30,	
	2017 Unaudited RMB'000	2016 Unaudited RMB'000
Cost of revenue	1,650	264
Sales and marketing expense	12,657	19,804
Administrative expenses	24,362	17,913
Product development expenses	16,152	18,438
Fulfillment	2,915	69
Total	57,736	56,488

At the end of the current reporting period, the Company had approximately 68,438,000 options and 67,356,000 RSUs outstanding under the Share Award Scheme. The exercise in full of the outstanding options and RSUs would, under the present capital structure of the Company, result in the issue of approximately 124,847,000 additional ordinary shares of the Company and additional share capital of approximately HK\$1,248,000 (equivalent to approximately RMB1,066,000) (before issue expenses), the purchase of approximately 8,531,000 existing shares from the market and release of approximately 2,416,000 treasury shares. The purchase of approximately 8,531,000 existing shares relate to RSUs to be vested, which are held by connected persons of the Group.

Subsequent to the end of the current reporting period, on October 11, 2017, the Company granted 11,739,000 options and 10,477,000 RSUs under the Share Award Scheme to eligible employees in respective of their services to the Group in the forthcoming years. These options have an exercise price of HK\$4.44 per option and vesting periods ranging from October 10, 2018 to October 10, 2021. The RSUs shall vest within four years from October 10, 2017. The price of the Company's shares at the date of grant was HK\$4.40 per share.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

21 OPERATING LEASE ARRANGEMENTS

At the end of the reporting period, the Group had total future minimum lease payments under non-cancellable operating leases falling due as follows:

	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
Within one year	15,542	14,312
In the second to fifth year inclusive	5,171	11,404
Over five years	—	80
	<u>20,713</u>	<u>25,796</u>

The Group leases certain of its offices buildings and warehouse under operating lease arrangements, which are negotiated for terms ranging from 6 months to 63 months.

22 COMMITMENTS

In addition to the operating lease commitments detailed in note 21 above, the Group had the following capital commitments at the end of the reporting period:

	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
Contracted, but not provided for:		
Capital injection in investees	<u>62,000</u>	<u>50,000</u>
	<u>62,000</u>	<u>50,000</u>

23 BUSINESS COMBINATIONS

(a) Business Combinations not under Common Control

On August 9, 2016, the Group acquired 100% equity interest in Guangzhou Wu Qian Nian Pharmaceutical Chain Co., Ltd.* (廣州五千年醫藥連鎖有限公司) (“**Wuqiannian**”) from certain third parties. The purchase consideration for Wuqiannian was in the form of cash amounting to RMB16,800,000. Total identifiable net assets at fair value as at acquisition date was approximately RMB3,193,000 and goodwill on acquisition was RMB13,607,000.

On September 23, 2016, the Group acquired 100% equity interest in Hangzhou Lihe Pharmaceutical Limited* (杭州禮和醫藥有限公司) (“**Lihe**”) from a third party. The purchase consideration for Lihe of RMB7,850,000 was in the form of cash, and fully paid on September 19, 2016. The fair values of total identifiable net assets of Lihe as at the date of acquisition was approximately RMB2,334,000 and goodwill on acquisition was RMB5,516,000.

(b) Business Combination under Common Control

The Group adopts merger accounting for common control combinations in respect of the following transaction which occurred during the six months ended September 30, 2017:

On June 30, 2017, the Group acquired 100% equity interest in Ali JK Nutritional Products Limited and its subsidiaries, Ali JK Nutritional Products HK Limited and Hangzhou Hengping Information Technology Co., Ltd.* (杭州衡平信息科技有限公司), (collectively referred to as the “**Ali JK Nutritional Products Group**”) from Ali JK Nutritional Products Holding Limited, or the “Vendor”, a direct wholly-owned subsidiary of Alibaba Holding. As the Company and Ali JK Nutritional Products Group are under the common control of Alibaba Holding before and after the acquisition, the business combination has been accounted for in the interim condensed consolidated financial statements of the Group as a business combination under common control using merger accounting.

Ali JK Nutritional Products Group was established by the Vendor to hold the business (the “**Target Business**”) which comprises: (i) all merchant relationships with the target merchants for the promotion and distribution of Blue Cap Health Food on Tmall.com; and (ii) certain relevant marketing and operations personnel managing the relationships with the target merchants. The Target Business earns software service fees from merchants when sales of Blue Cap Health Food on Tmall.com are completed.

The consideration amounting to HK\$3,800 million was satisfied by the Company issuing 1,187.5 million shares on June 30, 2017 to the Vendor. The market price of ordinary shares as at June 30, 2017 was HK\$3.72, representing a fair value of HK\$4,417.5 million (approximately to RMB3,831.6 million). The difference between the fair value of consideration shares issued amounting to approximately RMB3,831.6 million and the carrying amount amounting to approximately RMB3.0 million of the net asset of Ali JK Nutrition Products Group at acquisition date is recognised in merger reserve amounting to RMB3,828.6 million.

Since the acquisition, Ali JK Nutritional Products Group contributed RMB16,949,000 to the Group’s revenue and loss of RMB1,075,000 to the Group’s consolidated loss for the six months ended September 30, 2017.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

24 RELATED PARTY TRANSACTIONS

(I) Transactions with related parties:

In addition to the transactions detailed elsewhere in these financial statements, the Group had the following material transactions with related parties during the current reporting period:

	Notes	Six months ended September 30,	
		2017 Unaudited RMB'000	2016 Unaudited RMB'000
Services received from related parties:			
Cloud computing services received from Alibaba Cloud	(i)	(3,046)	(3,079)
Share based compensation paid to connected persons	(ii)	(15,323)	(10,764)
Services received from a joint venture	(iii)	(4,825)	(929)
Internet information and other related service received from relevant entities of Alibaba Group	(iv)	(26,474)	(25)
Shared services received from Alibaba Group	(v)	(9,295)	(1,732)
Marketing services received from a subsidiary of Alibaba Holding	(vi)	(1,840)	—
Logistics and warehouse services received from an associate of Perfect Advance	(vii)	(10,314)	—
Payment services received from Alipay	(viii)	(1,932)	N/A
Technical services received from Tmall entities regarding Blue Cap Health Food	(ix)	(7,933)	—
Promotion services purchased from an associate of Alibaba Group	(x)	—	(500)
Services provided to related parties:			
Outsourced and value-added services provided to Tmall Entities	(xi)	49,594	3,074
Tracking related services provided to a subsidiary of Alibaba Holding	(xii)	3,080	—
Others:			
Interest income from a joint venture	(xiii)	822	—

24 RELATED PARTY TRANSACTIONS (continued)**(I) Transactions with related parties: (continued)**

Notes:

- (i) On May 30, 2016, CITIC 21CN Technology and Alibaba Cloud Computing Ltd.* (阿里雲計算有限公司) ("**Alibaba Cloud**"), a subsidiary of Alibaba Group, entered into the Second Renewed Cloud Computing Service Agreement for a term of one year that runs retrospectively from April 1, 2016 to March 31, 2017, pursuant to which Alibaba Cloud, provided certain cloud computing services to the Group. On March 13, 2017, Alibaba Health Technology (China) Co., Ltd.* (阿里健康科技(中國)有限公司), an indirectly wholly-owned subsidiary of the Company, and Alibaba Cloud entered into the Third Renewed Cloud Computing Service Agreement for a term of one year, commencing from April 1, 2017 to March 31, 2018. Further details of the transactions were set out in the announcement of the Company dated March 13, 2017.
- (ii) On July 29, 2016, the Company granted a total of 2,509,000 options, with an exercise price of HK\$5.558 per share, and granted 1,065,000 RSUs to Mr. Wang Lei, the chief executive officer of the Company and certain employees of the Group, each of them either being a director of a subsidiary or certain subsidiaries of the Company, under the Share Award Scheme. Further details of the transaction were set out in the announcement of the Company dated July 29, 2016.

On June 14, 2017, the Company granted a total of 6,415,000 RSUs to Mr. Wang Lei and certain directors of a subsidiary or certain subsidiaries of the Company (other than insignificant subsidiaries as defined under the Listing Rules) under the Share Award Scheme.

- (iii) On April 3, 2015, April 1, 2016, November 7, 2016, September 1, 2016, April 3, 2017, and September 1, 2017, the Group entered into certain promotion service agreements and call center outsourcing service agreements with HL95 and one of its subsidiaries, pursuant to which HL95 will provide certain promotion service and call center services to the Group. The terms of the agreements are approximately one year commencing on the agreement date.
- (iv) On July 12, 2016, Alibaba Health Pharmaceutical Chain Co., Ltd.* (阿里健康大藥房醫藥連鎖有限公司) entered into a Tmall services agreement with the Tmall Entities, pursuant to which the Tmall Entities will provide internet information and other related services to the Group. The term of the Tmall services agreement was from July 12, 2016 to December 31, 2016. Further details of the transaction were set out in the announcement of the Company dated August 16, 2016. On December 31, 2016, the Company, Alibaba.com China Limited* (阿里巴巴網絡中國有限公司), and Taobao China Holding Limited entered into a service framework agreement, pursuant to which relevant entities[#] of Alibaba Group will provide to the Group internet information related software technical services and other related services. The contract commenced from March 11, 2017, being the date following approval at the special general meeting on March 10, 2017 and will end on March 31, 2018.

[#] Relevant entities refers to Alibaba (China) Technology Co., Ltd.* (阿里巴巴(中國)網絡技術有限公司), Hangzhou Alibaba Advertising Co., Ltd.* (杭州阿里巴巴廣告有限公司), Taobao China Holding Limited, the Tmall Entities and their respective affiliates, collectively.

- (v) On July 3, 2017, the Company entered into the Shared Services Agreement with Alibaba Holding, pursuant to which Alibaba Holding shall procure the Alibaba Service Providers[^] to provide to the Group the shared services for a term of one year with retrospective effect from April 1, 2017 to March 31, 2018.

[^] Alibaba Service Providers refers to Alibaba Holding, persons controlled by it and persons under the common control of Alibaba Holding, and any other persons designated by Alibaba Holding.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

24 RELATED PARTY TRANSACTIONS (continued)

(I) Transactions with related parties: (continued)

Notes: (continued)

- (vi) On August 4, 2016, Hangzhou Alimama Software Services Co., Ltd.* (杭州阿里媽媽軟件服務有限公司) (“Alimama”), a subsidiary of Alibaba Holding, and Alibaba Health Technology (China) Co., Ltd.* (阿里健康科技(中國)有限公司), an indirectly wholly-owned subsidiary of the Company, entered into an agency agreement to provide marketing services on the marketing and branding platform to Alibaba Health Technology (China) Co., Ltd.* (阿里健康科技(中國)有限公司) and its contracted clients for a term of nine months from July 1, 2016 to March 31, 2017. As the marketing agent, Alibaba Health Technology (China) Co., Ltd.* (阿里健康科技(中國)有限公司) would be entitled to receive certain incentive fees. Further details of the transaction were set out in the announcement of the Company dated January 6, 2017. On June 28, 2017, the Group and Alimama entered into the Renewed Agency Agreement for a term of one year, which runs retrospectively from April 1, 2017 to March 31, 2018. No incentive fee was incurred for the six months ended September 30, 2017. Further details of the transaction were set out in the announcement of the Company dated June 28, 2017.
- (vii) On September 20, 2016, Zhejiang Cainiao Supply Chain Management Co., Ltd.* (浙江菜鳥供應鏈管理有限公司) (“Cainiao”), an associate of Perfect Advance, and Alibaba Health (Hong Kong) Technology Company Limited, a wholly-owned subsidiary of the Company, entered into a Service Agreement, pursuant to which Cainiao will provide bonded warehouse services, customs clearance services and distribution services. The term of the Service Agreement was one year commencing on April 1, 2016 to March 31, 2017. On June 28, 2017, the Group and Cainiao entered into the Logistics Services Framework Agreement for a term of one year, commencing from April 1, 2017 to March 31, 2018. Further details of the transaction were set out in the announcement of the Company dated June 28, 2017.
- (viii) On September 20, 2017, the Company (for itself and on behalf of its subsidiaries) entered into the Payment Service Framework Agreement with Alipay.com Co., Ltd.* (支付寶(中國)網絡技術有限公司) (“Alipay”), a wholly-owned subsidiary of Ant Small and Micro Financial Services Group Co., Ltd.* (浙江螞蟻小微金融服務集團股份有限公司), a company incorporated in the PRC with limited liability, which together with its subsidiaries have been deemed by the Stock Exchange as connected persons of the Company on July 10, 2017, pursuant to which Alipay will provide payment services and the Group will pay service fees. The term of the Payment Service Framework Agreement is from July 10, 2017 to March 31, 2018. For the period from July 10, 2017 to September 30, 2017, a service fee of RMB1,932,000 was charged by Alipay to the Group.
- (ix) On May 18, 2017, a subsidiary of the Company entered into the Framework Technical Service Agreement with the Tmall Entities, pursuant to which the Tmall Entities will continue to provide technical support, internet information services and secondary domain names and other services for the operation of the Target Business as described in note 23(b) on Tmall.com. Tmall charged service fee of 50% of total software service fees received by the Target Business from the relevant merchants on Tmall.com. The Framework Technical Service Agreement was approved by the independent shareholders at special general meeting, and the term of the Framework Technical Service Agreement commenced on the day following completion of business acquisition under common control as described in note 23(b) and will end on March 31, 2020. For the six months ended September 30, 2017, a service fee of RMB7,933,000 was charged by the Tmall Entities to the Company. As at September 30, 2017, service fee payable to the Tmall Entities included in the Group’s account payable amounted to RMB7,260,000.
- (x) The purchase from an associate of Alibaba Group was made according to price and conditions offered to its major customers.
- (xi) On August 24, 2016, Alibaba Health Technology (China) Co., Ltd.* (阿里健康科技(中國)有限公司), an indirectly wholly-owned subsidiary of the Company, and the Tmall Entities, members of Alibaba Group, entered into a services agreement, pursuant to which the Group agreed to provide certain outsourced and value-added services in accordance with the terms and conditions of the services agreement. The Tmall Entities shall pay the Group a service fee amounting to 21.5% of the fees paid by the merchants to the relevant Tmall Entities in respect of the value of the completed sales of products or services under certain categories on Tmall. The transaction was approved by the Company’s independent shareholders at a special general meeting. The term of the services agreement was from September 13, 2016 to March 31, 2017. On March 10, 2017, Alibaba Health Technology (China) Co., Ltd.* (阿里健康科技(中國)有限公司), and the Tmall Entities renewed the service agreement for a term of one year, commencing from April 1, 2017 to March 31, 2018. Further details of the transaction were set out in the announcement of the Company dated August 24, 2016 and March 10, 2017.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

24 RELATED PARTY TRANSACTIONS (continued)

(I) Transactions with related parties: (continued)

Notes: (continued)

(xii) On September 26, 2017, Alibaba Health Technology (China) Co., Ltd.* (阿里健康科技(中國)有限公司), an indirect wholly-owned subsidiary of the Company, entered into the Tracking Service Agreement with Taobao China Holding Limited, an indirect wholly-owned subsidiary of Alibaba Holding, pursuant to which Alibaba Health Technology (China) Co., Ltd.* (阿里健康科技(中國)有限公司) shall provide development, maintenance and operation service of tracking information system to Taobao China Holding Limited for a term commencing on September 26, 2017 and ending on August 31, 2018.

(xiii) On January 1, 2017, HL95 entered into a loan agreement with Alibaba Health (Hong Kong) Technology Company Limited, a wholly-owned subsidiary of the Company, pursuant to which Alibaba Health (Hong Kong) Technology Company Limited agreed to provide a loan of RMB53,900,000 to HL95 for the three years ending December 31, 2019, which is unsecured and bears interest at a rate of 3% per annum.

The related party transactions (or certain aspects of such transactions) detailed in items (i), (ii), (iv) to (ix), (xi) and (xii) above for the current period also constitute non-exempt continuing connected transactions or connected transactions as defined in Chapter 14A of the Listing Rules.

(II) Outstanding balances with related parties

In addition to the outstanding balances detailed elsewhere in these financial statements, the balance with related parties as at September 30, 2017 and March 31, 2017 are listed below:

	September 30, 2017 Unaudited RMB'000	March 31, 2017 Audited RMB'000
(1) Amount due from related parties:		
Subsidiaries of Alibaba Holdings	27,270	26,135
Joint ventures	55,126	54,304
	82,396	80,439
(2) Amount due to related parties:		
Subsidiaries of Alibaba Holdings	29,807	5,810
Associate ^{&}	105,555	105,555
Joint ventures	3,258	4,627
	138,620	115,992

[&] The balance represented unpaid capital investment due to an associate of the Group.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended September 30, 2017

24 RELATED PARTY TRANSACTIONS (continued)

(III) Compensation of key management personnel of the Group

	Six months ended September 30,	
	2017 Unaudited RMB'000	2016 Unaudited RMB'000
Short term employee benefits	5,314	2,765
Share-based compensation expenses	14,487	10,764
Pension scheme contributions	101	94
Total compensation paid to key management personnel	19,902	13,623

25 SUBSEQUENT EVENTS

On October 4, 2017, the Company and Alibaba Holding entered into a facility agreement, pursuant to which Alibaba Holding agreed to on normal commercial terms grant an unsecured revolving credit facility of USD90,000,000 within one year. The loan shall be repaid before October 4, 2018. The interest rate of each loan was the London Interbank Offered Rate of loan period plus a margin of 1.8% per annum.

On October 9, 2017, the Company withdrew under the facility agreement an amount of USD12,000,000 (approximately to RMB80,000,400).

26 APPROVAL OF THE INTERIM FINANCIAL STATEMENTS

These interim condensed consolidated financial statements were approved and authorised for issue by the board of directors of the Company on November 15, 2017.

* For identification purpose only